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Introducti on & Outline of thesis
1
Dupuytren’s disease (DD) is a benign, progressive fi bromatosis of the palmar fascias of 
the hand and fi ngers, which leads to the formati on of nodules and cords, and may lead 
to disabling extension defi cits of the fi nger joints (Figure 1). Fibromatosis is a patho-
logical conditi on characterized by local proliferati on of fi broblasts and manifested 
clinically by soft  ti ssue thickening.1
The most common form is DD, with a prevalence that is reported between 0.6% 
and 31.6%.2 A study in Flanders (Belgium) revealed a prevalence of 32% in individuals 
over 50 years old, however, DD with fi nger contracti on was only present in 8% of this 
age group.3 In a study in the northern part of the Netherlands, a random sample of 
1,360 individuals was investi gated: in 17.9% of individuals there were nodules and 
cords present and 4.2% of individuals had fl exion contractures of the fi ngers.4 The 
prevalence of DD rises with increasing age5 and is most frequently found in Caucasian 
males.6
Treatment consists of division (fasciotomy) or surgical excision (fasciectomy) of the 
pathological cords, but other treatments are emerging.7,8 Recently Collagenase (col-
lagenase clostridium histolyti cum) injecti on has been approved for the treatment of 
Figure 1. Extensive ﬂ exion contractures of the metacarpalphalangeal and proximal interpha-
langeal joints of the index-, ring-, and litt le fi ngers are evident in the right hand of a pati ent 
with recurrent Dupuytren’s disease. All joints are at maximal possible extension.
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DD7 and lipofilling is being used in combination with percutaneous needle fasciotomy.9 
Radiotherapy can also be used in the early stages of the disease.10 However, there is no 
cure for the disease and reported recurrence rates vary from 8% to 85%, depending on 
the treatment modality.11-13
Even though DD has been recognized for several centuries and was first described as 
a medical condition by Plater of Basle in 1614,14 its pathogenesis remains unclear. The 
proliferating fibroblast and myofibroblast are the cells responsible for the flexion con-
traction in DD.15,16 These cells are characterized by the presence of α-smooth muscle 
actin, an actin isoform typical of vascular smooth muscle cells.17 Transforming growth 
factor (TGF)-ß is an important factor involved in the development of myofibroblasts 
and also promotes collagen formation, with a decrease of the ratio of type III to type 
I collagen.18
DD is associated with other fibromatoses, such as Peyronie’s disease (PD) and Led-
derhose’s disease (LD). PD is a localized fibromatosis of the penile tunica albuginea, 
leading to pain and/or a variety of deformities, which are most evident during erec-
tion.19 LD is a rare fibromatosis of the plantar aponeurosis, leading to nodules and 
pain in the foot.20 DD is also associated with factors such as smoking, use of alcohol, 
anti-epilepsy drugs, and medical conditions including liver disease and diabetes.21,22
The way DD develops in time varies. Some clinical characteristics of patients with DD 
are related to a more aggressive course of the disease or diathesis. In 1963, Hueston 
formed a hypothesis with the concept of a DD diathesis and pinpointed four factors to 
be involved: early onset of disease, bilateral involvement, positive family history, and 
the presence of ectopic lesions (knuckle pads, Ledderhose’s disease and Peyronie’s 
disease).23 Refinements of the DD diathesis have been made by Hindocha et al. and 
Abe et al.5,24
The clustering of DD in families, its prevalence in individuals of northern European 
descent, and its association with similar diseases (PD, LD) suggest a genetic influence 
on the development of the disease. Family studies mostly showed an autosomal 
dominant mode of inheritance for DD.25-28 Hu et al. established genetic linkage at a 
6 cM region on chromosome 16 in a single Swedish family.29 DD has also been sug-
gested to be a complex genetic condition, in which several genes and risk factors are 
involved, each conferring a certain (limited) risk to developing the disease. To date, a 
small number of candidate gene association studies have been performed in DD,30-32 
nonetheless, no causal variants have been found so far.
In recent years technical developments have made it possible to study genetic varia-
tion in genes throughout the genome on a single chip, and the costs of these genotyp-
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ing platf orms are becoming more aff ordable for researchers. It is widely recognized 
that a bett er understanding of the geneti c background of a disease may yield more 
insight into its pathogenesis. This may then lead to the development of new treatment 
modaliti es in the future.
Aim of this thesis
The general aim of this thesis was to investi gate the geneti c background of Dupuytren’s 
disease and its associated fi bromatosis. This knowledge will ulti mately lead to a bett er 
understanding of the disease and possibly to alternati ve treatments. In this thesis the 
following questi ons are addressed:
1. What is known about the geneti c basis of Dupuytren’s disease and which tools are 
available for geneti c studies?
2. What is the mode of inheritance of familial Dupuytren’s disease?
3. Which common geneti c variants are associated with Dupuytren’s disease?
4. Which common geneti c variants are associated with Peyronie’s disease?
5. Is there a shared geneti c background for Dupuytren’s disease and its associated 
fi bromatosis?
6. Are clinical characteristi cs (including the DD diathesis) in pati ents with Dupuytren’s 
disease associated with a higher geneti c risk for the disease?
Outline of this thesis
Chapter 2 provides an introducti on to basic geneti cs and explains the available geneti c 
techniques. It gives an overview of the geneti c studies that have been performed in DD 
to date and gives an insight into the plans for our future research.
In chapter 3, we describe eleven families (475 family members and 66 subjects diag-
nosed with DD) in order to investi gate the mode of inheritance of familial DD.
To identi fy suscepti bility genes for DD we performed a genome-wide associati on 
study, described in chapter 4. Initi ally, 960 Dutch pati ents with DD and 3,117 control 
persons were tested for associati on with the use of more than 300k single nucleoti de 
polymorphisms (SNPs). Subsequently, we tested the 35 SNPs most strongly associated 
with DD in three more independent cohorts, comprising 1,365 pati ents with DD and 
8,445 control persons in total.
Chapter 1
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Chapter 5 describes how we examined if the DD-associated variants identified in the 
genome-wide association study (chapter 4) also play a role in the genetic susceptibility 
of PD. We tested 111 men with PD and 490 controls for association for the nine DD 
SNPs identified in the genome-wide association study.
In chapter 6 the association between clinical characteristics (including the DD diathesis 
features) of patients with DD and their genetic risk for developing the disease (using 
the SNPs identified in the genome-wide association study) are investigated.
The main findings of this thesis are discussed in chapter 7 and future perspectives for 
studies in DD are given.
Finally, a summary and a Dutch translation of the summary can be found in chapter 8
17
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Introduction
The applicati on of Mendelian principles to heredity in man1 has opened the parti cular 
fi eld of human geneti cs and the experimental study of human traits. It was not before 
2001, when the draft  sequence of the human genome was published and thus the 
sequence of the nucleoti des, the chemical base pairs that make up DNA (and genes), 
was mostly determined,2,3 that we could study the human genome in its enti rety rather 
than one gene at a ti me.
Geneti c variati on, mostly represented by single nucleoti de polymorphisms (SNPs) 
and copy number variants (CNVs), is frequent; any two humans are diff erent in about 
0.5% of their DNA sequence. Mutati ons, i.e. permanent changes in the genome includ-
ing point mutati ons aff ecti ng single nucleoti des and structural changes of chromo-
somes, can predispose to developing disease, modify the course of disease, or cause 
the disease itself. Virtually any disease is the result of the combined acti on of genes 
and environment but the relati ve role of the geneti c component may be large or small. 
In a simplisti c way we can disti nguish monogenic and multi factorial diseases.
Monogenic disease is the result of a single mutated gene. These diseases, such as 
cysti c fi brosis and Hunti ngton’s disease, usually exhibit obvious inheritance patt erns in 
families according to the laws of Mendel. These patt erns can be autosomal dominant, 
recessive or X-linked. Most of such single-gene diseases are rare, with a frequency 
as high as 1 in 500 or 1,000 individuals but usually much less. Geneti c disorders may 
also be complex, meaning that they are associated with the eff ects of multi ple genes 
(polygenic) in combinati on with environmental factors (multi factorial). Multi factorial 
diseases include, among many others, forms of diabetes, cancer, cardiovascular dis-
ease, and psoriasis.
Dupuytren’s disease can be considered as a multi factorial disease as well. Although 
complex geneti c diseases oft en cluster in families, they do not have a clear (Mende-
lian) patt ern of inheritance. Multi factorial diseases have a major impact on the enti re 
populati on. The identi fi cati on of genes involved in Dupuytren’s disease will further 
our understanding of the pathogenesis and also provide insight into new treatment 
modaliti es.
Two fundamental approaches are available for identi fying genes involved in diseases 




The first approach, linkage analysis, is family based. Linkage analysis is a method that 
allows us to determine regions of chromosomes that are likely to contain a risk gene, 
and rule out areas where there is a low chance of finding a risk gene. This technique 
works by investigating the segregation of genetic markers to reveal recombination 
events between any two chromosomal loci. Currently, mostly SNPs are used as genetic 
markers. The location of approximately 3 million SNPs is presently known in the hu-
man genome. This means that there is one genetic marker (SNP) available in every 
1,000 base pairs of our DNA.
Linkage analysis involving specific genetic disease models is especially powerful for 
the study of rare single-gene diseases. In linkage studies, researchers are searching 
for a marker locus that is consistently inherited with a disease. To this end marker 
alleles are experimentally determined and their segregation followed in a pedigree. 
When a marker is found that co-segregates with the disease, the marker locus and 
the disease locus are said to be linked and assumed to be located near each other on 
a chromosome. The statistical estimate of whether two loci are linked to each other 
and therefore likely inherited together is called a LOD score. A LOD score above 3 is 
considered significant.
Association analysis
The second approach, association analysis, is population based. Association analysis 
is performed to determine whether a genetic variant (SNP) is associated with a dis-
ease. This technique is especially powerful for more common, genetically complex 
diseases.6,7 Most often a case/control study design is used. The allele frequencies 
of hundreds of thousands of markers (SNPs) spread over the genome are compared 
between cases (individuals with the disease) and controls from the same population. A 
significant difference in the frequency of an allele of a SNP between cases and controls 
indicates that the SNP is associated with the disease and may increase the risk of 
developing this disease. However, an associated SNP identified in an association study 
is usually not a disease causing variant but located on a stretch of DNA adjacent to this 
variant. This concept is called linkage disequilibrium (LD): the non-random association 
of alleles at two ore more loci in a population. An associated SNP therefore pinpoints 
a very small region of DNA with strong LD, which usually harbors only a few genes.
Because hundreds of thousands of markers have to be tested in a genome-wide 
association study, the possibility to detect false positive results is high. The easiest way 
25
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to reduce false positi ve fi ndings is a stringent signifi cance threshold. Generally a value 
p < 5.0 x 10-8 is accepted in studies of up to 1 x 106 markers. Another drawback in as-
sociati on analysis is populati on strati fi cati on. Populati on strati fi cati on is the presence 
of a systemati c diff erence in allele frequencies between subpopulati ons, usually due 
to a diff erent ancestry. Hence cases and controls must be from the same populati on. 
In order to provide evidence that associati ons are not false positi ve, it is furthermore 
important to replicate results in other study cohorts preferably from diff erent popula-
ti ons.
Genetic basis of Dupuytren’s disease
Dupuytren’s disease is a multi factorial disease. It has a strong geneti c component, 
as demonstrated by concordance rates in twin studies and familial clustering.8 The 
recurrence risk for persons with an aff ected sibling, for instance, was determined as 
λs = 2.9 in a populati on from England.9
There are few reports of extended pedigrees with a transmission of Dupuytren’s 
disease, which demonstrate an autosomal dominant inheritance with reduced pen-
etrance. In one pedigree from Sweden, a whole-genome linkage analysis has been 
conducted.10 It has localized a candidate region on chromosome 16, an underlying 
mutati on, however, has not yet been identi fi ed. Other studies have used a case/
control design for the analysis of an associati on with parti cular functi onal candidate 
genes such as those involved in the TGF-b pathways. Markers in the genes for TGF-b1, 
TGF-b2, or TGF-b receptors have not proven an associati on so far. Only a SNP in the 
gene for transcripti on factor Zf9, which may acti vate TGF-b1, showed an associati on 
with an odds rati o of 1.9.11
In order to systemati cally elucidate the geneti c basis for Dupuytren’s disease, we 
have decided to use our study cohorts for genome-wide associati on studies in a case/
control study design. As outlined above, large sample numbers are necessary for 
whole-genome associati on studies, in order to gain suffi  cient power to obtain signifi -
cant results. The 2010 Internati onal Symposium on Dupuytren’s Disease has initi ated 
the collaborati on of research groups from the Netherlands, Germany and UK, involving 
the insti tuti ons of the authors, departments from Oxford (UK), and several others. 
Unti l now we have incorporated more than 1,000 Dutch cases, more than 600 German 
cases, and more than 700 UK cases. This joint endeavour made it possible to perform 
a large scale genome-wide associati on study including the chip-based analysis of very 
large numbers of SNPs, i. e., up to 1 x 106 markers distributed over the human genome. 
Chapter 2
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Experimental procedures and data analysis are done in an automated manner. The 
data analysis also involves several statistical tools to remove false positive findings and 
test against systematic genotyping errors, genetic selection, and population stratifica-
tion. These and other problems are for instance addressed by strictly taking account 
of the Hardy-Weinberg equilibrium (HWE), which regards the genotype distribution at 
a single locus in the population. Finally, our collaborations also allow for powerful rep-
lication studies, which are considered as an important part of a strong genome-wide 
association study. The most significant results of this cooperative study identifying 
several loci associated with Dupuytren’s disease will soon be published elsewhere. 
These approaches are only first steps to characterize the genetic basis for Dupuytren’s 
disease. However, they are an important undertaking, since only the subsequent char-
acterization of the molecular etiology will lead to the development of more effective 
and possibly causal treatment opportunities for Dupuytren’s disease.
27
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Although several studies on the genetic origin of Dupuytren’s disease have been 
performed, the mode of inheritance is still not clear. We describe 11 pedigrees with 
familial Dupuytren’s disease from the Netherlands.
Patients with Dupuytren’s disease with two or more affected first-degree relatives 
were asked to participate in the study together with their family. In five families, all 
members were clinically examined. In the six other families, the diagnosis of Dupuy-
tren’s disease was based on information provided by the proband. All participants 
completed an extensive questionnaire.
Eleven pedigrees, consisting of 475 family members and including 66 subjects 
diagnosed with Dupuytren disease, were studied. Of the affected family members, 
67% were male and 33% female. Paternal transmission was observed in 45% of cases 
and maternal transmission in 55% of cases. Fifty-two percent of the offspring of the 
affected individuals also have Dupuytren’s disease.
Our data suggest an autosomal dominant mode of inheritance for familial Dupuy-
tren’s disease, but with a reduced penetrance. This confirms previous studies.
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Introduction
Dupuytren’s disease is a benign, progressive fi brosing disorder of the palmar fascias of 
the hand and fi ngers, which leads to the formati on of nodules and cords, and may lead 
to disabling extension defi cits of the fi nger joints. Treatment consists of division or 
surgical excision of pathologic cords, but there is a high recurrence rate aft er surgery 
in pati ents with the Dupuytren’s disease diathesis.1
Dupuytren’s disease has been recognized for several centuries and was fi rst de-
scribed as a medical conditi on by Plater of Basle in 1614.2 Its pathogenesis remains 
largely unknown. The reported prevalence of Dupuytren’s disease varies from 3-42%,3 
with the highest incidence in Caucasians, while it is rarely seen in Africans.4 Men are 
seven ti mes more oft en aff ected than women, but in later life the incidence in women 
increases to the same as in men.3 Some suggest that the disease symptoms are milder 
in women and therefore may remain unnoti ced for a longer period.5
The clustering of Dupuytren’s disease in families suggests a geneti c infl uence on 
the onset of the disease. Several studies on the geneti c origin of Dupuytren’s disease 
have been performed,5-15 but its mode of inheritance is sti ll not clear. Multi ple re-
ports describe Dupuytren’s disease as an autosomal dominant disease with varying 
penetrance.16-18 An allele with a reduced penetrance means that some disease gene 
carriers do not develop the disease phenotype. Table 1 presents an overview of the 
family studies performed on Dupuytren’s disease.
The most recent one was published by Hu et al. who presented a single Swedish family 
with a clear autosomal dominant mode of inheritance.13 But there are many sporadic 
(non-familial) cases of the disease that are not compati ble with a Mendelian inheri-
tance patt ern.5 In a review in 1999, Burge et al. suggested that recessive inheritance 
sti ll remains a viable hypothesis for Dupuytren’s disease.5 In two candidate-gene as-
sociati on studies by Bayat et al., the genes for TGFßR and Zf9 were only signifi cantly 
associated with Dupuytren’s disease when using a recessive model.9,10 Another pos-
Table 1. Review of the English-language literature
Author Year Journal No. of 
families
Aff ected/total no. 
family members
Mode of inheritance
Ling et al. 1963 J Bone Joint Surg Br 34 151/832 Autosomal dominant
Maza et al. 1968 J Hered 1 4/16 Autosomal dominant
Matt hews et al. 1979 Br J Plast Surg 1 13/42 Autosomal dominant*
Hu et al. 2005 Clin Genet 1 18/50 Autosomal dominant
* Matt hews et al. reported a family with predominantly aff ected females (Males:Females = 4:9).
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sible hypothesis is that Dupuytren’s disease is a complex trait in which several genes 
and risk factors are involved, each conferring a certain (limited) risk to developing 
the disease. It is known that factors such as smoking, use of alcohol, anti-epilepsy 
drugs, and medical conditions including liver disease and diabetes, are associated 
with a higher prevalence of the disease,3,19 complicating the picture even further. 
Since Dupuytren’s disease is considered to be one of the most common hereditary 
connective tissue disorder in Caucasians,12 finding genes for this disease is of utmost 
importance to understanding the disease pathogenesis and for developing diagnostic 
and prognostic protocols.
We investigated the clinical characteristic of families with Dupuytren’s disease and 
examined the mode of inheritance. Here we describe 11 pedigrees with familial Du-
puytren’s disease from the Netherlands. The results of this work will significantly aid 
in designing proper genetic studies to identify the underlying gene(s).
Material and Methods
We identified Dupuytren patients visiting the outpatient clinics, who had two or more 
first-degree relatives with the disease. They were asked to participate in this study and 
family members were contacted via the proband. All participants signed an informed 
consent and this study was approved by the Medical Ethics Committees.
All the subjects (including probands, affected and unaffected family members) of five 
families were personally examined by trained clinical researchers or plastic surgeons with 
substantial clinical experience in treating Dupuytren’s disease. The diagnosis was based 
on the presence of characteristic Dupuytren nodules and/or cords in the palm of the 
hand and/or digits, with or without contractures of the digits. All probands and affected 
family members were asked to complete a questionnaire on the age of onset, presence 
of suggested risk factors (diabetes, alcohol consumption, liver disease, anti-epileptic 
medication), occupation, hobbies, and the presence of recurrent disease. In most cases 
the hands of the affected individuals were also photographed. Information about de-
ceased family members was gathered via the proband and other family members.
In the six remaining families, the diagnosis of Dupuytren’s disease was based on 
information provided only by the proband; the family members were not clinically 
examined.
Data were entered into a database (Excel 2003; Microsoft, US). To investigate the 
genetic transmission of Dupuytren’s disease in these families, pedigree charts were 
reconstructed from the data obtained from all 11 families using pedigree-drawing 
software (Cyrillic; Cyrillic software, UK). The mean age of onset of Dupuytren’s disease 
33
A clinical geneti c study of familial Dupuytren’s disease in the Netherlands
3
in pati ents with a positi ve family history in a study by Hindocha et al. was 49 years.12 
Therefore, unaff ected family members under the age of 49 were included in the 
pedigrees, but were not considered in the analysis of the inheritance patt ern, because 
of the age-dependent penetrance of Dupuytren’s disease. Healthy family members 
suspected of being a carrier of the disease gene were used in the analysis of the 
transmission patt ern. These unaff ected carriers have at least one aff ected fi rst-degree 
family member and one aff ected child. All the families who parti cipated in this study 
between January and December 2007 are described in this paper.
The pedigrees encompassed 475 family members, with 66 subjects diagnosed with 
Dupuytren’s disease. Of the aff ected family members, 44 (67%) were male and 22 
(33%) were female. Five of the pedigrees spanned three generati ons and six pedigrees 
spanned four generati ons.
Results
Demographics and mode of inheritance
We describe the mode of inheritance of 11 pedigrees with Dupuytren’s disease (Table 
2) and the detailed clinical characteristi cs of fi ve of these families (Table 3). All family 
members were Caucasians and originated from the northern part of the Netherlands.
In the selected pedigrees, two individuals were thought to be unaff ected carriers 
because they had transmitt ed the disease to the next generati on. This suggested an 
incomplete penetrance in at least 3% (2/68) of the Dupuytren carriers, assuming a 
dominant model of inheritance. All types of transmission were observed (male to 
male, male to female, female to female, female to male). Paternal transmission was 
observed in 45% of cases and maternal transmission in 55%. Fift y-two percent of the 
off spring of the aff ected individuals have Dupuytren’s disease. The inheritance pat-
tern of Dupuytren’s disease in these pedigrees was compati ble with an autosomal 
dominant mode of inheritance with slightly reduced penetrance (95%). Penetrance is 
the proporti on of individuals carrying a disease gene that also expresses this disease.
Description of selected pedigrees
Family 1
This family spanned four generati ons and consisted of 76 family members, with nine 
aff ected. Of the aff ected family members, fi ve were male and four were female. The 
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Table 3. Clinical characteristi cs of aﬀ ected individuals in 5 families with Dupuytren’s disease












1 I:2 f 60-69 - + -
1 II:1 m 60-69 - - - - -
1 II:4 f 70-79 - - - - -
1 II:5 m 70-79 - - - - -
1 II:10 f 30-39 - + - - -
1 II:11 m 30-39 + + - - -
1 III:1 m 50-59 - + - - -
1 III:30 f 30-39 - + - - +
1 III:32 m 30-39 - + - - -
2 II:4 f 50-59 + + - - +
2 II:5 m 50-59 + - - - -
2 II:7 m 40-49 - - - - +
3 II:3 m 60-69 + + kn - -
3 II:4 m 60-69 - - - - -
3 II:6 m 40-49 + - - - -
3 II:11 f 60-69 - + - - -
3 II:15 m 50-59 + - kn - -
3 II:17 m 50-59 - + - epilepsy stopped 
1974
3 III:9 m 30-39 - - - - -
4 II:5* m ? ? ? ? ? ?
4 III:1 m 40-49 + + - diabetes -
4 III:3 m 40-49 - + - - +
4 III:5 m 40-49 + - pd - stopped 
1998
4 III:21 f 50-59 - - - - +
4 III:24 m 40-49 + - - - stopped 
2000
5 II:1 m 50-59 + + - - -
5 II:2 f 60-69 - + - - -
5 III:1 m 40-49 + - kn/ld - -
5 III:3 m 30-39 + + kn/ld/pd - -
* The clinical characteristi cs of individual II:5 in family 4 are unknown.
Kn: Knuckle pads, Ld: Ledderhose’s disease, pd: Peyronie’s disease
Chapter 3
36
member II:11 and his children III:30 and III:32 displayed an early onset of the disease 
(before age 40).
Family 2
This family spanned three generations, with 33 family members, of whom three were 
affected. In the first generation the grandparents, who were unrelated, did not develop 
the disease, however the grandfather (I:1) died at the early age of 39 years. Except for 
individual III:1 (50 yrs,) the entire third generation was younger than 49 years old.
Family 3
In this three-generation family, 8 out of 54 family members were affected. In the 
second generation, 6 out of 12 individuals were affected. Individual III:9 (42 yrs), who 
developed the disease before the age of 40, was the only affected family member 
in the third generation. His father, II:6, was the only affected person in the second 
generation who demonstrated Dupuytren’s disease before the age of 50.
Family 4
This three-generation family had 48 members, of whom six were affected. It is not 
known whether the grandparents were affected. Individual II:1 was presumed to be an 
unaffected carrier. The fourth generation is not shown, since they are all younger than 
40 years and so far unaffected.
Family 5
In this small family, both parents in the second generation (II:1 and II:2) were affected 
by Dupuytren’s disease, with the father having an age of onset between 50 and 59 
years and the mother between 60 and 69 years. Individuals III:1 and III:3 showed the 
first signs of the disease before the age of 44. They have both been treated three times 
with a selective fasciectomy. III:1 and III:3 not only display the disease in both hands 
including knuckle pads, but also in their feet (Ledderhose’s disease), while individual 
III:3 also has a benign progressive fibrosing disorder affecting the penis (Peyronie’s 
disease).
All pedigrees were compatible with an autosomal dominant mode of inheritance.
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Discussion
We describe the mode of inheritance and the clinical characteristi cs of families with 
Dupuytren’s disease in order to further elucidate the geneti cs of this familial disorder. 
Probands and their relati ves of fi ve families were interviewed and examined. Informa-
ti on on six additi onal families was collected via six other probands.
The sex-distributi on of aff ected individuals male:female was 2:1 (67%:33%). As 
noted by Ross, women develop Dupuytren’s disease approximately a decade later and 
the sex-distributi on will consequently be nearly equal by the ninth decade of life.3 This 
explains the relati vely small diff erence in the sex-distributi on found in this study.
Paternal and maternal transmission was observed in 45% and 55% of cases, respec-
ti vely. Fift y-two percent of the off spring of aff ected individuals was also aff ected at age 
49 years or older. These data, in combinati on with the appearance of the pedigrees, 
are compati ble with an autosomal dominant mode of inheritance for a late-onset 
disease in these families.
From the families described, it is apparent that the decade of onset of the disease 
seen in the parents also predicts the age of onset for their off spring. For instance, in 
family 1, individual II:11 developed Dupuytren’s disease in the fourth decade (30-39 
yrs) just as his off spring (III:30 and III:32). In family 3, III:9 was the only aff ected person 
in the third generati on so far. His father (II:6) was the only individual aff ected under 
the age of 50 in the second generati on of this family.
In family 2, the grandfather (I:1) might have been a carrier of the disease. He died 
aged 39 and had probably not developed Dupuytren’s disease at that stage.
Figure 5. Family 5
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In family 5 individuals III:1 and III:3 not only displayed an earlier onset than their par-
ents, but also a far more aggressive form and at different locations. The co-existence 
of Dupuytren’s disease with Ledderhose’s disease and Peyronie’s disease has been 
noted frequently. Since both their parents are affected, individuals III:1 and III:3 could 
be homozygous for the mutation of this apparently dominant disease. Ling et al. also 
observed a more severe clinical manifestation of the disease in individuals with both 
parents affected.16
Table 3 shows the clinical characteristics of the affected individuals in the five fami-
lies, but there are no apparent patterns. Two factors complicate the resolving of the 
genetic mechanism of Dupuytren’s disease: the late age of onset and its fairly high 
incidence in the general population. Our data suggest that the most likely mode of 
inheritance in these families with Dupuytren’s disease is autosomal dominant with a 
reduced penetrance, which confirms previously published data.
Since only Dupuytren patients with two or more affected first-degree relatives were 
asked to participate in this study, there will have been an ascertainment bias. Sporadic 
cases of the disease were excluded in this design, hence alternative modes of inheri-
tance cannot be ruled out. To prevent this bias, all Dupuytren patients presenting at 
the outpatient clinics should have been included. Furthermore, to improve the power 
of this study more families need to be included and all family members should be 
examined by an experienced clinician.
The large pedigrees with multiple affected patients with Dupuytren’s disease will 
be instrumental in the genetic mapping and identification of genetic factors involved 
in Dupuytren’s disease by using classical linkage approaches. Genes identified in this 
way may also help to resolve the disease etiology of the sporadic form of Dupuytren’s 
disease. This knowledge will ultimately lead to improved diagnosis and possibly to 
alternative treatments.
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Dupuytren’s disease is a benign fibromatosis of the hands and fingers that leads to 
flexion contractures. We hypothesized that multiple genetic and environmental fac-
tors influence susceptibility to this disease and sought to identify susceptibility genes 
to better understanding its pathogenesis.
Methods
We conducted a genome-wide association study of 960 Dutch persons with Dupuy-
tren’s disease and 3,117 controls (the discovery set) to test for association between 
the disease and genetic markers. We tested the 35 single nucleotide polymorphisms 
(SNPs) most strongly associated with Dupuytren’s disease (P<1x10-4) in the discovery 
set in three additional, independent case series comprising a total of 1,365 affected 
persons and 8,445 controls from Germany, the United Kingdom and the Netherlands.
Results
Initially, we observed a significant genome-wide association between Dupuytren’s 
disease and 8 SNPs at three loci. Tests of replication and joint analysis of all data from 
2,325 patients with Dupuytren’s disease and 11,562 controls yielded an association 
with 11 SNPs from nine different loci (P<5.0x10-8). Six of these loci contain genes 
known to be involved in the Wnt-signaling pathway: WNT4 (rs7524102, P = 2.81x10-9, 
OR 1.28), SFRP4 (rs16879765, P = 5.63x10-39, OR 1.98), WNT2 (rs4730775, P =3.02x10-8, 
OR 0.83), SULF1 (rs2912522, P = 2.01x10-13, OR 0.72), RSPO2 (rs611744, P = 7.87x10-15, 
OR 0.75), and WNT7B (rs6519955, P = 3.24x10-33, OR 1.54).
Conclusions
This study implicates nine different loci involved in genetic susceptibility to Dupuy-
tren’s disease. The fact that six of these nine loci harbor genes encoding proteins in 
the Wnt-signaling pathway suggests that aberrations in this pathway are key to the 
process of fibromatosis in Dupuytren’s disease.
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Introduction
Dupuytren’s disease (DD) is a benign fi bromatosis of the hands and fi ngers, giving rise 
to the formati on of nodules and cords and oft en leading to fl exion contractures. The 
prevalence of DD is reported to be between 0.2% and 56%.1 Men are more oft en af-
fected than women, but by the ninth decade of life, the incidence in women is the same 
as that in men.2,3 Standard treatment consists of surgical excision or transecti on of 
pathologic nodules and cords, but other methods of treatment are emerging.4,5 There 
is no cure for the disease, however, and reported recurrence rates range from 8% to 
66%, depending on the treatment.6,7 The pathogenesis of DD is not fully understood.
The clustering of cases of DD in families suggests a geneti c infl uence on the onset of 
disease; however, it is probably a complex conditi on, in which several geneti c and en-
vironmental risk factors are involved, each contributi ng in small part to suscepti bility 
to the disease. To date, a limited number of small candidate-gene associati on studies 
have been performed,8,9 but no causal genes have been identi fi ed. To identi fy common 
geneti c variants associated with this disease, we carried out a genome-wide associa-
ti on study involving 960 persons with DD and 3,117 controls, all from the Netherlands 
and of European descent.
Methods
Subjects
Parti cipants provided writt en informed consent, and we obtained approval from an 
insti tuti onal review board to carry out the study. Between 2007 and 2010 we recruited 
960 pati ents with DD through the outpati ent clinics of the plasti c surgery depart-
ments of six hospitals in the Netherlands. All 3,117 controls for the discovery set were 
drawn from LifeLines, a large, populati on-based cohort study being conducted in the 
northern Netherlands.10 We obtained blood samples for replicati on studies from 189 
Dutch pati ents with DD, as well as from 561 Dutch controls who were newly enrolled 
in LifeLines and for whom genotyping data were already available; from 711 Briti sh 
pati ents with DD, as well as from 5,984 controls from the Wellcome Trust Case Control 
Consorti um 2 (WTCCC, 1958 Birth Cohort and UK Nati onal Blood Service) for whom 
genotyping data were already available,11 and from 465 German pati ents with DD, as 
well as from 1,900 controls, for 1,618 of whom genotyping data were already available 
(1,164 from the PopGen study at the University of Kiel and 454 from KORA [Coopera-
ti ve Health Research in the Region of Augsburg] at the Helmholtz Center Munich in 
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questi onnaire, the choices being Dutch, European (specify country), and other (specify 
country). DNA samples were obtained from either blood samples (in the Dutch and 
German case series) or saliva (in the UK case series).
Tests for Association
We genotyped the Dutch samples (discovery set) and control samples (LifeLines) with 
Illumina HumanCytoSNP-12 arrays, comprising 301,232 SNPs, and called SNPs with the 
use of the Illumina algorithm (Genome Studio version 2.10.1). To test for replicati on of 
associati on, we selected SNPs that showed an associati on in the discovery set with a 
P value of less than 10-4. We confi rmed the integrity of these associati ons by manually 
inspecti ng genotype clusters and selected two SNPs to represent each independent 
locus. We genotyped the SNPs selected for tests of replicati on in the Dutch and Brit-
ish persons by means of KASP by design assays (KBioscience). We used the Human 
SNP Array 6.0 (Aff ymetrix) to genotype these SNPs in the German persons. To test for 
replicati on of SNPs for which no direct or tag SNPs were present on the Aff ymetrix 6.0 
platf orm, we genotyped the selected SNPs in both the German persons aff ected with 
DD and a separate control series, using GenomeLab SNPstream (Beckman Coulter).
Statistical analysis
We excluded from the analysis specifi c SNPs and data from specifi c samples as de-
scribed previously.12,13 SNPs with call rates of less than 95%, a minor-allele frequency 
of less than 0.01, or deviati on from Hardy-Weinberg equilibrium (P<0.0001) were 
excluded, as were samples with call rates below 99% or with a discrepancy between 
recorded sex and genotype-inferred sex. We also excluded relati ves and ethnic outli-
ers. Because genome-wide associati on studies are performed in pati ents and controls 
in the same ethnic group, we used multi dimensional scaling in the study parti cipants 
and persons in HapMap to identi fy nonwhites in our study populati on (i.e., ethnic out-
liers). We compared genotype prevalence in cases and controls with the use of a basic 
chi-square allelic test with 1 degree of freedom and calculated the over-dispersion 
factor of associati on test stati sti cs (genomic control infl ati on factor, λGC) with the use 
of observed versus expected values for all SNPs by means of the PLINK soft ware pack-
age (version 1.07). Principal component analysis was performed with the use of the 
EIGENSTRAT soft ware package to control for populati on strati fi cati on. We conducted 
conditi onal analysis with the use of SNPTEST, version 2, when more than one SNP with 
a signifi cant genome-wide associati on clustered at a certain region.
We excluded SNPs from tests of replicati on if they had a call rate below 98% or devi-
ated from Hardy-Weinberg equilibrium (P<0.0001), and we excluded samples with call 
rates below 95%. We carried out a joint analysis of the discovery and replicati on phases 
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Table 2. The 35 SNPs selected for replication and the tag SNPs used in the UK and German series 
are shown (with r2 value).
Chr SNP
UK series German series
Tag SNP r2 Tag SNP r2
1 rs7524102 – – – –
3 rs1123148 – – – –
3 rs2323206 – – – –
3 rs1356802 – – – –
4 rs6824106 – – – –
5 rs11743146 – – – –
5 rs11745128 rs11743146b 0.98 rs11743146a 1.00
6 rs7747741a – – – –
6 rs2179367 – – – –
6 rs237018 rs237012 1.00 – –
7 rs16879765 – – – –
7 rs1668357 – – – –
7 rs4730775 rs6951125 1.00 rs6951125 1.00
7 rs4719773a – – – –
8 rs1365415 rs13269711 1.00 rs13269711 1.00
8 rs611744 rs423940 0.84 rs423940 0.84
8 rs2912522a – – – –
9 rs10809642 – – rs7863802 1.00
9 rs10809650 – – – –
10 rs7072865 rs11188849b 0.87 rs11188849 0.88
12 rs638791 rs616559 1.00 – –
12 rs2073950 – – – –
12 rs12372139 – – – –
15 rs4932194a – – – –
15 rs6496520 – – rs7168492 0.96
15 rs2171286 – – rs17302219 1.00
17 rs4789939a – – – –
18 rs504302 rs474605 0.87 rs474605 0.87
18 rs1944967 – – rs625896 1.00
19 rs11672517a – – – –
20 rs6029273 rs742745 1.00 rs742745 1.00
20 rs8124695 rs6093338 1.00 rs6093338 1.00
22 rs8140558 rs6519955b 0.87 rs6519955a 0.96
22 rs4820663a – – – –
22 rs6519955a – – – –
a SNPs genotyped with GenomeLab SNPstream in a separate German control series of 282 indi-
viduals. The other replication SNPs were present in the German control series genotyped on the 
Affymetrix 6.0 platform (1,604 individuals). b SNPs imputed from WTCCC control data. This imputed 
data was generated with BEAGLE Genetic Analysis Software Package based on HapMap 2 in CEU 
(individuals of European ancestry).
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with the use of Cochran-Mantel-Haenszel strati fi cati on. In the UK control series, not all 
SNPs selected for replicati on were available on the Illumina 1.2M and Aff ymetrix 6.0 
genotyping platf orms, which were used by WTCCC; in some cases, we used tag SNPs, 
and for four replicati on SNPs, we used imputed WTCCC control data (Table 2) gener-
ated with BEAGLE Geneti c Analysis Soft ware Package 3.2 and based on the HapMap 
phase 2 reference of the Centre d’Etude du Polymorphisme Humain (CEPH) persons of 
European ancestry (CEU). In the German series, several SNPs selected for replicati on 
were not available on the Aff ymetrix 6.0 platf orm; in these cases, tag SNPs were used 
as well (Table 2). We used multi ple genotyping platf orms for the control cohorts in the 
replicati on phase. Since the replicati on signals were in the same directi on and of the 
same magnitude as the discovery results, it is unlikely that the confi rmatory results 
were due to biased genotyping. We checked for inter-platf orm reproducibility by 
comparing genotypes of the same samples between diff erent platf orms and showed 
concordance rates of more than 99.99%.
We were not able to correct for populati on strati fi cati on in the samples used to test 
for replicati on because we genotyped only a limited number of SNPs in this phase. 
Meta-analysis of the discovery and replicati on data was also performed with PLINK 
soft ware. We performed an analysis with the use of the Gene Relati onships across 
Implicated Loci (GRAIL) stati sti cal strategy involving hg18 and PubMed data sets (De-




Data obtained through genome-wide genotyping of aff ected persons and con-
trols are stored at the European Genome-Phenome Archive (accession number, 
EGAS00000000043). We excluded 66,293 SNP genotypes because they did not meet 
quality-control criteria, leaving 234,939 SNPs typed in 856 pati ents with DD and in 
2,836 controls (Table 1). The call rate for the remaining SNPs was 99.9%. There was 
moderate evidence for infl ati on in the test stati sti c (λGC = 1.21). Adjustment for dif-
ferenti al populati on strati fi cati on with the use of the fi rst fi ve components on the 
basis of a principal component analysis of uncorrelated SNPs reduced the infl ati on 
to λGC = 1.19. Figure 1 shows that the case and control groups were well matched for 
populati on strati fi cati on aft er correcti on for these components. We found that the 
infl ati on was caused by geneti c heterogeneity between persons in the north and south 
of the Netherlands and noted diff erences in case pati ents between the clinics (Figure 
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2). After exclusion of case patients from the most southern and eastern hospitals in 
the Netherlands, the inflation decreased to 1.07 (Figure 3 and 4). There were no signs 
of differences in SNP call rates between case patients and controls. After correction for 
the inflation factor, the quantile-quantile plots of the logarithms of our genome-wide 
P-values shows 83 data points above the expected diagonal line (Figure 5a).
Figure 1. Plots of principal components 2 and 4 from the PCA, including all subjects of the 
GWAS and HapMap 2. 
a: before removal of the first 5 components. b: after removal of the first 5 components.
Figure 2. Principal component analysis of our DD cases, shown per clinic.
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In the genome-wide associati on study, we identi fi ed eight SNPs at three loci that 
showed signifi cant associati on (P< 5x10-8)(Figure 5b). On chromosome 7, we identi -
fi ed a locus with four signifi cantly associated SNPs. Associati on was strongest at 
rs16879765, which lies within the gene encoding ependymin-related protein 1 (EPDR1)
(P = 1.9x10-16; odds rati o (OR) = 1.94). The three other associated SNPs were in linkage 
disequilibrium with the top SNP: rs1668357 (r2 = 0.57), rs1668347 (r2 = 0.59), rs952368 
(r2 = 0.44). Similarly, three signifi cantly associated SNPs were identi fi ed at a single 
locus on chromosome 22. The most signifi cant SNP on 22q, rs6519955 (P = 2.75x10-13; 
Figure 3. Locati on of the six parti cipati ng clinics and the region from which the ‘LifeLines’ co-
hort is being built up (shaded grey) in the Netherlands.




OR = 1.56), is located between Wingless-type MMTV integration site family member 
7B (WNT7B) and LOC100271722, a hypothetical non-coding RNA gene. The two other 
associated SNPs on chromosome 22 were in linkage disequilibrium with the top SNP: 
rs8140558 (r2 = 0.96), rs4072455 (r2 = 0.75). A conditional analysis to adjust for the 
top SNPs for these two loci showed no independent signals, suggesting that there 
is one pivotal genetic variation that drives the association of the neighboring SNPs. 
One additional putative DD associated locus was identified on chromosome 19, with a 
single significant SNP (rs11672517)(P = 2.76x10-8; OR = 1.46).
Tests of Replication
To test for replication of our initial findings, we selected 35 SNPs from 24 independent 
loci that met the significance threshold of P<1x10-4 in the discovery phase. We col-
lected genotype data for the 35 SNPs in three different populations of case patients 
and controls, from the Netherlands, the United Kingdom and Germany (1,365 case 
patients with DD and 8,445 controls before quality control). One SNP (rs10809642) 
failed on genotyping in the Dutch and UK replication series and four SNPs (rs1123148, 
rs2179367, rs638791 and rs12372139) failed genotyping because of a laboratory error 
in the German series. One SNP (rs1668357) was out of Hardy-Weinberg equilibrium 
Figure 5. Results of the Genome-wide Association Study in Dupuytren’s Disease. 
The genome-wide P-values were obtained with the use of a basic chi-square allelic test with 1 
degree of freedom, corrected for genomic inflation, for 234,939 SNPs in 856 DD patients with 
DD and 2,836 controls from the Netherlands. Panel A is a quantile-quantile plot of observed P 
values for association (blue) and after removal of SNPs within 1 megabase of the nine regions 
identified as significant after meta-analysis (green). The red line represents concurrence of the 
expected and the observed P values. Values above the red line indicate a signal in the data. Panel 
B is a Manhattan plot showing the genome-wide P values (-log10) plotted against their respec-
tive positions on each chromosome. The horizontal red line shows the genome-wide significance 
threshold of 5.0 x 10-8.
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(P<0.0001) in all three replicati on series and was therefore excluded from further 
analysis. Eleven SNPs from nine diff erent regions showed clear evidence of replica-
ti on aft er correcti ng for the 35 tested SNPs (P<0.0014 and associati on with the same 
allele and in the same directi on as in the discovery phase) and reached genome-wide 
signifi cance in a meta-analysis (P< 5.0 x 10-8)(Table 3). All loci that showed signifi cant 
associati ons in the discovery set also showed signifi cant associati ons in the replica-
ti on set: rs16879765 on 7p14.1 (P=5.63 x 10-39, OR 1.98), rs6519955 (P=3.24x10-33, OR 
1.54) and rs8140558 (P=1.20x10-22, OR 1.39) on 22q13 and rs11672517 on 19q13.4 
(P=6.81x10-14, OR 1.34). Two SNPs of borderline signifi cance in the discovery set 
showed signifi cant associati on in the tests of replicati on: rs2912522 (P=2.01x10-13, OR 
0.72) on 8q13, and rs8124695 (P=7.60x10-10, OR 1.48) on 20q11.2-q13.1. Four addi-
ti onal SNPs also reached genome-wide signifi cance: rs611744 on 8q23.1 (P=7.87x10-15, 
OR 0.75), rs10809650 (P=6.15x10-9, OR 0.80) and rs10809642 (P=1.21x10-8, OR 1.35) 
on 9p24.3, and rs7524102 (P=2.81x10-9, OR 1.28) on 1p36.23-p35.1.
For 2 of the 11 SNPs with a genome-wide signifi cant associati on, we used tag SNPs 
with less than complete linkage disequilibrium or imputed SNPs in the meta-analysis 
(Table 2). We genotyped one of these SNPs, rs611744, on the Immunochip platf orm in 
8,274 UK controls (Table 1) and observed associati on (P=1.8 x 10-14) on meta-analysis. 
The other SNP, rs8140558, is one of two SNPs at the WNT7B locus. In additi on, a meta-
analysis for this SNP that excluded the data from the UK and German case series (since 
these data were only indirectly genotyped [Table 2]) showed a signifi cant genome-
wide associati on (P=4.8x10-16) (Table 4).
Regional plots of the nine DD risk loci are shown in Figure 6. To gain insight into 
the biological mechanisms and to fi nd genes functi onally related at these regions, we 
applied GRAIL analysis. The 11 SNPs at the nine regions that had a signifi cant genome-
wide associati on were used as query regions, resulti ng in the analysis of 22 unique 
genes. We found a total of seven associati ons with SNPs (P<0.05), including four SNPs 
implicati ng four WNT genes (P< 0.0001 for each) (Table5). When these results were 
corrected for multi ple testi ng (22 tests), the associati ons with SNPs implicati ng the four 
WNT genes (rs7524102-WNT4, rs4730775-WNT2, rs6519955-WNT7B and rs611744-
RSPO2) remained signifi cant (P<0.003). We observed no associati on between the 
identi fi ed SNPs with a signifi cant genome-wide associati on and gene expression in six 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4. Results for rs611744 using 8,274 UK controls on the Immunochip platform and the re-
sults for rs8140558 without using the UK and German case series.
P-values
Chr SNP Locus GWAS Dutch UK German Follow-up Meta
8 rs611744 RSPO2 4.4 x 10-5 6.5 x 10-3 9.2 x 10-9 NA 2.1 x 10-10 1.8 x 10-14
22 rs8140558 WNT7B 1.5 x 10-11 5.7 x 10-4 NA NA 5.7 x 10-4 4.8 x 10-16
Table 5. The genome-wide significant SNPs with a GRAIL P-value < 0.05
SNP Gene GRAIL P-value*
rs7524102 WNT4 5.2 x 10-6*
rs8140558 WNT7B 2.2 x 10-5*
rs6519955 WNT7B 2.2 x 10-5*
rs4730775 WNT2 2.3 x 10-5*





*P-values are uncorrected. Correction for 22 tests requires a P-value < 0.0023. P-values indicated 
with an asterisk withstand the multiple testing correction.
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Figure 6. Regional plots of the nine Dupuytren’s disease risk loci identified in this study.
The P-values obtained in the discovery phase using a 1-degree-of-freedom basic c2 allelic test 
corrected for genomic inflation (y-axis) were plotted against their chromosomal map positions 
(x-axis). Per region, the most significant SNP in the meta-analysis is plotted in purple and in a 
diamond shape. The color of each SNP spot reflects its r2 linkage disequilibrium value. Estimated 
recombination rates were plotted in blue.3 a: region on chromosome 1. b: region 1 on chromo-
some 7, EPDR1 and SFRP4 are located near rs16879765. c: region 2 on chromosome 7. d: region 
1 on chromosome 8. e: region 2 on chromosome 8. f: region on chromosome 9. g: region on 
chromosome 19. h: region on chromosome 20. i: region on chromosome 22, SNPs rs6519955 and 
rs8140558 are in linkage disequilibrium with each other (r2 = 0.96).
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Discussion
We identi fi ed nine chromosomal loci associated with suscepti bility to DD. Very litt le is 
known about the heritability of this disease, since there are only a few reports from 
family and twin studies.15-17 Our fi ndings suggest that common geneti c variants have 
an important causati ve role in DD in Northern European populati ons.
A GRAIL analysis showed that four diff erent DD risk loci contain genes that encode 
proteins in the Wnt-signaling pathway: 1p36.23-p35.1, containing WNT4 (rs7524102); 
7q31.2, containing WNT2 (rs4730775); 22q13, containing WNT7B (rs6519955); and 
8q23.1, containing RSPO2 (rs611744). Three other associated loci also contain WNT 
genes, although they were not implicated on GRAIL analysis: 7p14.1, containing SFRP4 
(rs16879765); 8q13, containing SULF1 (rs2912522); and 6q25.1, containing TAB2 
(rs2179367). However, the last of these three did not reach genome-wide signifi cance 
(Pmeta=2.47x10
-7).
The WNT gene family consists of structurally related genes that encode glycopro-
teins, extracellular signaling molecules. Abnormal Wnt-signaling is linked to a range 
of diseases, especially cancer. The best understood Wnt-signaling pathway is the 
canonical pathway, which acti vates the nuclear functi ons of ß-catenin, leading to 
changes in gene expression that infl uence cell proliferati on and survival.18 Abnormal 
proliferati on of fi broblasts is a key feature of early development of DD. The disease 
can be divided into three histological stages: stage 1, proliferati on of fi broblasts; stage 
2, diff erenti ati on of fi broblasts into myofi broblasts; and stage 3, formati on of mature 
type 1 collagen.19,20 Wnt-signaling is known to regulate the proliferati on and diff er-
enti ati on of fi broblasts in both cancer and fi bromatosis.21 Most of our knowledge of 
Wnt-signaling is derived from studies of cancer. In colon cancer, up-regulati on of WNT-
signaling causes intesti nal crypt cells to proliferate for longer than usual before they 
migrate and diff erenti ate.22 This prolonged proliferati on phase results in the formati on 
of polyps and confers a predispositi on to cancer.
The involvement of the Wnt-signaling pathway in the pathogenesis of DD is con-
sistent with features of the disease and with established aspects of Wnt-signaling. 
An imbalance of Wnt-signaling in DD could cause fi broblasts in the fascia of the hand 
to proliferate and form nodules. Indeed, increased levels of ß-catenin have been ob-
served in DD primary cell cultures in vitro,23 suggesti ng that the Wnt-signaling pathway 
is oversti mulated in DD.
The WNT proteins, WNT2, WNT4 and WNT7B, which were identi fi ed on GRAIL analy-
sis, bind to Frizzled receptors, leading to a cascade of events that eventually result in 
a decrease in the rate of β-catenin degradati on (Figure 7).18 Secreted frizzled-related 
proteins, such as SFRP4, antagonize the Wnt-signaling pathway by binding to either 
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WNTs or Frizzled receptors, thereby aff ecti ng receptor occupancy. In the absence of 
acti ve WNT, ß-catenin is degraded, and potenti al target genes will not be acti vated.
Another DD risk locus contains RSPO2, encoding an R-spondin; members of the 
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Figure 7. Signaling pathways of WNT and ß-catenin. 
The nine suscepti bility regions in DD include three WNT genes, one gene for secreted frizzled-
related protein (SFRP), and one gene for R-spondin (RSPO2) genes. Panel A shows that in the 
absence of WNT protein, ß-catenin (ß-cat) is degraded, and forthcoming target genes are in 
a repressed state. Panel B shows that if WNT signaling is acti ve, ß-catenin degradati on is re-
duced. SFRPs antagonize the Wnt-signaling pathway by binding to either WNT or frizzled recep-
tor, thereby aff ecti ng receptor occupancy. R-spondin positi vely regulates ß-catenin signaling by 
interacti ng with the frizzled receptor and the low-density lipoprotein-receptor-related protein 
(LRP5/6) and by competi ng with dickkopf protein (DKK).18-31 APC denotes adenomatous polypo-
sis coli, CBP cyclic AMP response-element– binding (CREB) protein–binding protein, CK1 casein 
kinase 1, DSH disheveled protein, GBP GSK3-binding protein, GSK3 glycogen synthase kinase 3, P 
phosphorylati on, SFRP secreted frizzled-related protein, and TCF T-cell factor.
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signaling. Furthermore, R-spondins induce canonical Wnt-signaling by competi ng with 
dickkopf (DKK) protein for binding to LRP5/6. The DKK protein is an inhibitor of Wnt-
signaling; it hinders the formati on of a complex between WNT, Frizzled receptor and 
LRP5/6 (Figure 7).24 SULF1, a Heparan sulfate 6-O-endosulfatase, is known to infl uence 
canonical Wnt-signaling. How it does so is not clear, but 6-O-desulfati on of heparan 
sulfate proteoglycans may alter the binding of WNT to its Frizzled receptor.25,26 In-
creased acti vity of these WNT and R-spondin genes or a decreased acti vity of SFRP 
could sti mulate Wnt-signaling and reduce intracellular ß-catenin degradati on. This 
mechanism could trigger fi broblasts to proliferate, leading to the development DD.
Also supporti ng a role for Wnt-signaling in DD is the microRNA (miRNA) expression 
profi les of fi broblasts and palmar fascia in persons with this disease, as compared 
with those of healthy controls. These miRNAs regulate genes related to the ß-catenin 
pathway: WNT5A, ZIC1, and TGFB1.27
The three remaining signifi cant loci lack an obvious connecti on to the WNT pathway. 
An interesti ng candidate gene from these regions is MAFB. The RNA of MAFB has 
been shown to be up-regulated in the excised cord ti ssue from persons with DD, as 
compared to fascia of the hand in healthy controls.28 Maf proteins are known for their 
role in fi brosarcoma and are believed to infl uence ti ssue development and cellular 
diff erenti ati on.29 MAFB can transform primary fi broblasts in vitro.30 The gene might 
therefore be involved in stage 2 of DD (the diff erenti ati on of fi broblasts into myofi bro-
blasts). The miRNA expression profi le associated with DD implicated some miRNAs in 
infl uencing the expression of MAFB as well.27
The results of our study indicate that geneti c factors have a major role in the devel-
opment of DD. Associati ons with variati ons in genes that encode proteins in the Wnt-
signaling pathway suggests that aberrati ons in this pathway confer suscepti bility to the 
disease. Further geneti c and basic research in this fi eld is required to fully unravel the 
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Peyronie’s disease (PD) is a fibromatosis of the penis, with a pathology very similar to 
what is seen in the hand (palmar fascia) in Dupuytren’s disease (DD). Recently, we per-
formed a genome-wide association study and identified nine genetic loci containing 
common variants associated with DD. Seven of these loci mapped within or near genes 
of the canonical WNT pathway and each locus yielded relatively large odds ratios (ORs) 
for DD disease status.
Aim
Given the clinical overlap between PD and DD, we examined whether the nine DD 
susceptibility loci are also involved in PD.
Methods
An association study was performed using a case/control design. From 2007 to 2010, 
we prospectively included 111 men who had been clinically diagnosed with PD. Control 
subjects (n=490 males) were randomly drawn from a population-based cohort from 
the same region of the Netherlands. Allele frequencies in the 111 PD cases and 490 
controls were compared using a 1-degree-of-freedom basic chi square test. A P-value 
< 0.05 after Bonferroni correction for the nine tested single nucleotide polymorphisms 
(SNPs) was considered statistically significant (i.e. P < 0.0056).
Main Outcome Measures
Association of genetic markers (SNPs) with PD
Results
We observed significant association with SNP rs4730775 at the wingless-type MMTV 
integration site family member 2 (WNT2) locus on chromosome 7 (P = 0.0015, OR 
0.61), but found no evidence for the other eight loci being involved with PD despite 
the large effect size seen for some of these variants in DD. The WNT2 association was 
even more significant after we removed 15 patients with co-morbid DD.
Conclusions
WNT2 is a susceptibility locus for PD and our finding provides evidence for a partly 
shared genetic susceptibility between PD and DD.
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Introduction
Peyronie’s disease (PD) is a localized fi bromatosis of the penile tunica albuginea (TA), 
the fi brous layer of connecti ve ti ssue covering the corpora cavernosa of the penis. PD 
may present with pain and/or a variety of deformiti es, which are most evident during 
erecti on as TA compliance is compromised at the plaque. The curvature and loss of 
rigidity may compromise sexual intercourse and thereby seriously aff ect the quality of 
life of pati ents and their partners.
The prevalence of PD in the general populati on is esti mated to be as high as 3-9%. 
1,2 PD is thought to be under-reported because of embarrassment, poor screening, or 
because it is considered an unavoidable consequence of aging.3 The eti ology of PD is 
sti ll not fully understood. Repeti ti ve minor trauma during sexual intercourse, followed 
by abnormal wound healing and scar formati on, has been suggested as a mechanism 
of plaque formati on.4 A geneti c predispositi on to the development of PD has also been 
proposed. Nyberg et al. showed that PD was transmitt ed in an autosomal dominant 
patt ern in three families.5 However, no suscepti bility locus has been identi fi ed so far.
A variety of co-morbiditi es have been associated with PD, including cigarett e 
smoking, radical prostatectomy, diabetes mellitus, hyperlipidemia, hypertension and 
Dupuytren’s disease (DD).6-8 In a recent cross-secti onal study, DD was shown to be 
the only co-morbidity factor which was signifi cantly associated with PD, with a co-
morbidity rate ranging widely, from 1.5–39%.9
DD is characterized by fi brosis of certain fascias of the hand and fi ngers with similar 
fi broti c alterati ons to those seen in PD. As the myofi broblast is an essenti al cellular 
component of DD nodules, a common pathophysiology of PD and DD has been sug-
gested. This was substanti ated by the observati on of similar alterati ons in gene expres-
sion in PD and DD.10
We recently performed a genome-wide associati on study (GWAS) in 2,325 DD 
cases and 11,562 populati on controls; this revealed nine suscepti bility loci for DD with 
relati vely large eff ect sizes (odds rati o (OR) of 1.25-1.98).11 Given these results, we 
examined whether the DD-associated variants identi fi ed in the GWAS also play a role 
in PD suscepti bility.
Materials and Methods
Patient population
We had 121 PD pati ents available for this study; they were prospecti vely recruited at 
the outpati ent clinic of the Urology Department, University Medical Center Groningen, 
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the Netherlands from 2007 to 2010. Written informed consent was given by all pa-
tients, and the Institutional Review Board approved the study. PD was diagnosed by an 
experienced urologist based on palpation of a plaque and available photographs of the 
erect penis. The diagnosis of DD was based on the presence of characteristic nodules 
and/or cords in the palm of the hand, with or without contracture of the digits. We 
collected clinical information, including age of onset, and treatment modality. We also 
collected 10 ml of venous blood from each subject for DNA extraction using standard 
methods.
Five hundred male control subjects, of whom genotype data were already available, 
were randomly drawn from the ‘LifeLines’ cohort, a large population-based study cur-
rently being conducted in the northern Netherlands.12 No phenotypic information with 
regard to DD or PD was available for these subjects; there was no overlap between the 
control subjects for the genome-wide association study on DD11 and those used for 
this study.
Genotyping
Nine SNPs that were previously associated with DD11 were genotyped using KASP as-
says (KBioscience, Hoddesdon, Herts, UK) (Table 1). For all the control individuals we 
had Illumina CytoSNP-12 (Illumina, San Diego, CA, USA) data, comprising more than 
300,000 SNPs and including the nine SNPs associated with DD. To corroborate that no 
genotyping bias is introduced due to difference by genotyping platform, we performed 
individual genotyping of these nine SNPs in 96 individuals using KASP and different 
Illumina SNP arrays and observed 100% concordance rate.
Statistics
We used PLINK 1.07 for quality control and statistical analysis.13 SNPs were excluded 
when the call rate < 98%, or when deviation from Hardy Weinberg equilibrium (HWE) 
was observed (P < 0.05); samples were removed from further analysis when call rates 
< 95%. Quality control was performed separately in the case and control groups and 
repeated after merging the genotype data. We were not able to correct for popula-
tion stratification, since only the nine SNPs were genotyped in the PD patient group. 
However, all patients were Caucasians from the Netherlands.
Allele frequencies in the PD cases and controls were compared using a 1-degree-of-
freedom basic chi square test. A P-value < 0.05 after Bonferroni correction for the nine 
tested SNPs was considered statistically significant (i.e. P < 0.0056).
Statistical power calculations using the odds ratios and allele frequencies of the pre-
vious DD GWAS indicated that, given the sample size of this study, the power ranged 
between 26% and 98% for the different loci (Table 1).
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The mean age of patients at the time of diagnosis was 56.8 years (standard deviation 
(SD) ± 9.7) and the mean age of PD onset was 51.9 years (SD ± 10.2). Fifteen patients 
(13.5%) were also affected with DD.
We excluded 10 PD subjects and 10 controls because of low genotyping rates for 
the 9 SNPs, leaving 111 patients and 490 control subjects for further analysis. There 
were no signs of differences in SNP call rates between cases and controls in the data. 
The genotype rate in the remaining individuals was 100% with no genotype exclusion 
based on HWE criteria.
The results of the association analysis are listed in Table 2. We observed significant 
association with SNP rs4730775, which is located at wingless-type MMTV integration 
site family member 2 (WNT2) with an uncorrected P = 0.0015, and OR of 0.61 (95% 
confidence interval (CI) 0.45-0.83) (Figure 1, Table 2). Excluding the 15 PD cases with 
co-morbidity of DD revealed an even more significant association, with an uncorrected 



































Figure 1. Regional linkage disequilibrium plot for SNP rs4730775 on chromosome 7 (based on 
1000 Genomes data, pilot 1 in CEPH [CEU]). This figure was generated with SNP Annotation 
and Proxy Search.20
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To examine whether the DD-associated variants identified in the GWAS also play a role 
in PD susceptibility, we performed this association study.
We observed significant association with SNP rs4730775 (WNT2). The association 
was even more significant after we removed 15 patients with co-morbid DD, which 
proves that the association is caused by PD and not by DD. None of the other loci 
yielded a significant result with PD, even though power calculations had indicated a 
very high likelihood of finding a significant association for rs16879765 (98%, Table 1) 
assuming similar ORs between PD and DD.
The fact that we find rs4730775 to be associated with PD in this relatively small 
cohort (with an a priori power of 26% based on DD findings) may suggest that this 
locus has more effect on the origin of PD than DD. For the remaining seven loci (not 
including rs16879765 with a power of 98%), the power was < 57% indicating that we 
were less likely to replicate these loci in this study anyway.
An OR < 1 for the A-allele at rs4730775 (0.61) means that this allele is protective 
for developing PD as it is also protective for developing DD. However we do not know 
yet if this improves or deteriorates the function of WNT2 or other genes at this locus. 
WNT2 is a strong candidate gene for PD pathogenesis. WNT2 is a member of the WNT 
gene family, which consists of structurally related genes that encode glycoproteins. 
These act as extracellular signaling factors. WNT2 is especially associated with gastro-
intestinal cancer and is also used as a tumor marker of gastric and colorectal cancer.14 
The best understood Wnt-signaling pathway is the canonical pathway, which activates 
the nuclear functions of ß-catenin, leading to changes in gene expression that influ-
ence cell proliferation and survival.15
A recent study identified increased levels of ß-catenin, the end-product of Wnt-sig-
naling, in TA-derived cells from PD patients compared to cells from normal TA tissue.16 
This suggests that the Wnt-signaling cascade is over-stimulated in PD. Wnt-signaling is 
known to regulate proliferation and differentiation of fibroblasts in both cancer and 
fibromatosis.17 This mechanism may trigger fibroblasts to proliferate excessively as 
observed in the process of developing PD.
Flanking WNT2 we found two other genes (Figure 1): ST7 that encodes for a low-
density lipoprotein receptor-related protein that interacts with proteins related to 
signal transduction pathways,18 and ASZ1 (or GASZ) that encodes for a germ cell pro-
tein, which is essential for male meiosis.19 There is no functional data at this time that 
would support involvement of these genes in the susceptibility of PD or DD, however.
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The strong aspects of this study are the prospecti ve design and the fact that all PD 
pati ents were examined by a single experienced urologist. Limitati ons are the sample 
size and the absence of a replicati on cohort.
We have identi fi ed WNT2 as suscepti bility locus for PD and provide evidence for a 
partly shared geneti c suscepti bility between PD and DD. The fact that we did not fi nd 
evidence for involvement of the SFRP4 locus with PD despite a stati sti cal power of 98% 
based on previous DD fi ndings suggests that there may also be some disti nct geneti c 
suscepti bility factors between the diseases. However, larger follow-up studies are re-
quired to establish this more fi rmly. The strong geneti c fi ndings for these disorders 
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Dupuytren’s disease (DD) is a benign fibrosing disorder of the hand and fingers. Re-
cently, we identified 9 single nucleotide polymorphisms (SNPs) associated with DD in 
a genome-wide association study. These SNPs can be used to calculate a genetic risk 
score for DD. The aim of this study was to test whether certain clinical characteristics 
(including the DD diathesis features) of patients with DD are associated with a high 
genetic risk score.
Methods
Between 2007 and 2010, we prospectively invited all DD patients (1,120 in total) to 
participate. Clinical characteristics were noted using patient- and doctor-completed 
questionnaires, and blood was obtained for DNA analysis. We analyzed a total of 933 
subjects with genetic and clinical data. The 9 previously identified DD SNPs were used 
to calculate a weighted genetic risk score. Patients were categorized into high and 
low genetic risk score groups, according to their weighted genetic risk score. Logistic 
regression was performed to study the association of clinical characteristics with a 
high genetic risk score.
Results
In a univariate regression model, patients with an age of onset of DD younger than 50 
years, a family history positive for DD, knuckle pads, and Ledderhose’s disease were 
statistically significantly associated with a high genetic risk score. In an additional 
analysis using high and low genetic risk groups that deviate further from the median, 
Ledderhose’s disease was no longer significantly associated with DD.
Conclusions
Patients with DD who present with these diathesis features, and predominantly pa-
tients with knuckle pads, are more likely to carry more risk alleles for the discovered 
DD SNPs than patients without these diathesis features.
Clinical Relevance
These markers may prove useful in predicting disease progression or recurrence.
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Introduction
Dupuytren’s disease (DD) is a benign fi brosing disorder of palmar fascias of the hand 
and fi ngers leading to the formati on of nodules and cords. Oft en these cords contract, 
causing fl exion contractures of the fi ngers. The prevalence of DD has been reported to 
vary between 0.2 and 56%.1 The prevalence of DD rises with increasing age,2 and DD is 
found most frequently in Caucasian males.3 Standard treatment consists of collagenase 
injecti on, and percutaneous division or surgical excision of the nodules and cords.4,5 At 
present, the disease is incurable and recurrence rates following treatment vary from 
8% to 66%, depending on the treatment modality and defi niti on of recurrence.5-7 DD is 
associated with several environmental factors, such as alcohol consumpti on, smoking, 
and anti epilepti c drug use, as well as with diseases such as diabetes mellitus and liver 
disease.8
The way DD develops varies over ti me. Some clinical characteristi cs of pati ents 
with DD are related to a more aggressive course of the disease or diathesis. In 1963, 
Hueston9 postulated the idea of a DD diathesis and described 4 factors defi ning this 
subset of disease: early onset of disease, bilateral involvement, positi ve family his-
tory, and the presence of ectopic lesions (knuckle pads, Ledderhose’s disease, and 
Peyronie’s disease). In 2006, male sex as a diathesis factor was added, “early onset of 
disease” was refi ned to age of onset younger than 50 years, and the ectopic lesions 
were restricted to the presence of knuckle pads only.2 Features of the DD diathesis 
were used also in a scoring system by Abe et al. in 2004 to evaluate the risk of recur-
rence and extension of DD for a Japanese populati on, implicati ng a more aggressive 
course of the disease.10 These authors suggested the additi on of radial side involve-
ment and litt le fi nger involvement to the diathesis scoring list.
The clustering of DD in families has long been recognized and most geneti c studies 
have reported an autosomal dominant inheritance patt ern.11,12 Recently, we suggested 
that DD is a complex geneti c disorder, in which several geneti c and environmental risk 
factors are involved, each contributi ng to disease suscepti bility.13 Nine SNPs associ-
ated with DD were identi fi ed in a 2-stage genome-wide associati on study in 2,325 DD 
pati ents and 11,562 populati on controls. These SNPs represent the presently known 
geneti c DD profi le and can be used to calculate a geneti c risk score for DD in each 
pati ent; the more risk alleles a pati ent carries, the higher the geneti c risk score will be 
for that pati ent.14
We hypothesized that there is an associati on between certain clinical characteristi cs 
and the geneti c risk score of pati ents with DD. Therefore, the aim of this study was to 
test whether clinical characteristi cs (including the diathesis features) of DD pati ents 




Between 2007 and 2010, we prospecti vely invited all pati ents evaluated for a diag-
nosis of DD at the outpati ent clinics of the plasti c surgery departments of 6 hospitals 
in the Netherlands to parti cipate. In this period a total of 1,120 pati ents gave their 
consent (see fl ow chart, Figure 1). Pati ents were diagnosed by plasti c surgeons with 
substanti al clinical experience in treati ng DD. The diagnosis was based on the presence 
of characteristi c nodules and/or cords in the palm of the hand and/or digits, with or 
without contracture of the digits. Writt en informed consent was acquired from all 
pati ents, with insti tuti onal review board approval. Pati ents were asked to complete 
a questi onnaire inquiring about details concerning their clinical characteristi cs includ-
ing age of onset, familial involvement, level of educati on, hand labor, medical history, 
and medicati ons. A positi ve family history was defi ned as the presence of at least 1 
other aff ected family member as noted by the pati ent. For 58 pati ents the pati ent’s 
questi onnaire was not available (Figure 1). The plasti c surgeons completed a separate 
 
Dupuytren’s Disease patients 
N = 1,120 
Genotype data passing Quality 
Control 
N = 991 
Genotype data failed Quality 
Control 
N = 129 
Patient questionnaire not available 
N = 58 
Patient questionnaire available 
N = 933 
 
Doctor questionnaire available 
N = 566 
Doctor questionnaire not available 
N = 367 
Figure 1. Inclusion ﬂ ow chart.
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questi onnaire on the clinical characteristi cs of these pati ents, including passive ex-
tension defi cits in metacarpophalangeal (MCP), proximal interphalangeal (PIP), and 
distal interphalangeal (DIP) joints, unilateral or bilateral disease, the number of rays 
involved, and the presence of ectopic deposits (knuckle pads, Ledderhose’s disease, 
and Peyronie’s disease). For 367 pati ents the doctor’s questi onnaire was not available 
(Figure 1). We did not collect clinical data concerning radial side involvement and litt le 
fi nger involvement as used in the scoring system by Abe et al.10 Blood was obtained 
from all pati ents for DNA analysis.
Genetic and statistical analysis
Details about genotyping and quality control steps have been described previously.13 
One hundred twenty-nine DNA-samples did not pass standard quality control and 
were excluded from further analysis (Figure 1). The 9 SNPs that were found to be 
associated with DD were at an individual basis used to calculate a weighted geneti c 
risk score (wGRS).
The wGRS of each pati ent was calculated by multi plying the number of risk alleles 
per SNP by the weight for that SNP, taking the sum across the SNPs, and dividing this 
number by the 9 SNPs according to the following formula:
where i is the SNP, n is the number of SNPs, wi is the weight for SNP i, and Xi is the 
number of risk alleles. The natural log of the odds rati o (OR) for each allele was used 
for the weight. For this wGRS calculati on, PLINK soft ware (version 1.07),15 a tool set for 
geneti c analysis, was used.
The more risk alleles that are carried by a pati ent, the higher the wGRS. The wGRS 
scores were primarily divided in 2 categories (low and high score), where all scores 
below the median were considered as low score and all the scores equal to or higher 
than the median were considered as high score. An additi onal analysis was performed 
in which the groups were subdivided into categories that deviated further from the 
median. The low geneti c risk score group was defi ned as a wGRS lower than 1 standard 
deviati on (SD) from the median and the high geneti c risk score group as a wGRS higher 
than 1 SD from the median. These categories were designed arbitrarily.
All data were transcribed categorically by using binary variables. Because the doc-
tor’s questi onnaire was not available for all pati ents, a chi-square test was used to 
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compare the patient groups with and without a doctor’s questionnaire. We thereafter 
performed univariate logistic regression to study the association of clinical character-
istics with the presence of a high genetic score and calculated ORs and 95% confidence 
intervals. P < 0.05 was considered as statistically significant.
Results
An overview of the clinical characteristics noted in the patient’s and doctor’s question-
naires is shown in Table 1 and Table 2, respectively. Of the 933 patients who completed 
the patient’s questionnaire, 711 (76%) were male and 222 (24%) were female. There 
were no differences in the frequencies of clinical characteristics between the patients 
with or without a completed doctor’s questionnaire (Table 1).
The median wGRS of the 933 patients was 0.009 (ranging from -0.044 to 0.064, see 
also Figure 2). Based on the wGRS, 461 patients were below the median and classified 
as the low genetic risk score group (including 282 patients with a completed doctor’s 
questionnaire), and 472 patients were above the median and classified as the high 
genetic risk score group (including 284 patients with a completed doctor’s question-
naire).
Table 1. Relevant clinical characteristics, patient’s questionnaire (N = 933)













Male 711 (76%) 421 (74%) 290 (79%) P=0.104
Female 222 (24%) 145 (26%) 77 (21%)
Age of onset
< 50 355 (39%) 208 (37%) 147 (41%) P=0.251
≥ 50 561 (61%) 350 (63%) 211 (59%)
Family history for DD
Positive 461 (50%) w 270 (48%) 191 (52%) P=0.208
Negative 468 (50%) 293 (52%) 175 (48%)
DD, Dupuytren’s disease.
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The OR of having a high geneti c risk score were signifi cantly greater in pati ents with 
an age of onset of DD younger than 50 years of age, a family history positi ve for DD, 
knuckle pads, and Ledderhose’s disease (Tables 3 and 4). An additi onal analysis was 
performed, in which the low geneti c risk score group was defi ned as a wGRS lower 
than 1 SD from the median and the high geneti c risk score group as a wGRS higher 
than 1 SD from the median. Age of onset of DD younger than 50 years of age, a family 
history positi ve for DD, and knuckle pads signifi cantly predicted a high geneti c score in 
this additi onal analysis (Table 5).
Discussion
The goal of this study was to test whether selected clinical characteristi cs of pati ents 
with DD were associated with a high geneti c risk score. Pati ents were categorized into 
high and low geneti c score groups according to their wGRS. In a univariate regression 
model, age of onset of DD younger than 50 years of age, a family history positi ve for 
Table 2. Relevant clinical characteristi cs, doctor’s questi onnaire (N = 566)
Clinical Characteristi cs N (%)
Number of Aff ected Rays
<3 390 (74%)
≥ 3 139 (26%)
Total passive Extension Deﬁ cit
<45o 298 (54%)















Table 3. Predicti on of characteristi cs pati ent’s questi onnaire on high geneti c risk score using a 
univariate logisti c regression analysis.
Variable OR 95% CI P-value
Sex
Male 1.28 0.94-1.73 0.11
Female 1
Age of onset
<50 1.35 1.04-1.77 0.03
≥ 50 1
Family history for DD
Positi ve 1.58 1.22-2.04 0.001
Negati ve 1





















Std. Dev. = ,01669376945
N = 933
Page 1
Figure 2. Histogram of geneti c risk scores.
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DD, knuckle pads, and Ledderhose’s disease were signifi cantly associated with a high 
geneti c risk score.
The OR’s of the signifi cant diathesis features varied from 1.35-1.95, each having only 
a moderate eff ect on predicti ng a high geneti c risk score. This is related to the fact 
that the study populati on was primarily divided into 2 large subgroups (geneti c risk 
scores higher or lower than the median), in which most pati ents had a geneti c score 
with a value almost equal to the median. When the groups were further subdivided 
into categories that deviated 1 SD from the median, age of onset of DD younger than 
50 years of age, a family history positi ve for DD, and knuckle pads remained signifi cant 
with, as expected, larger eff ect sizes (Table 5). The presence of Ledderhose’s disease-
ceased to be signifi cant in the additi onal analysis and was only just signifi cant in the 
primary analysis. Further research has to demonstrate if Ledderhose’s disease is really 
associated with a high geneti c risk score.
Table 4. Predicti on of characteristi cs doctor’s questi onnaire on high geneti c risk score using a 
univariate logisti c regression analysis.
Variable OR 95% CI P-value
Number of Aff ected Rays
≥ 3 0.87 0.59-1.28 0.47
<3 1
Total passive Extension Deﬁ cit
≥ 45 o 1.22 0.87-1.71 0.24
<45 o 1
Knuckle pads present
Yes 1.95 1.20-3.18 0.01
No 1
Ledderhose’s disease present
Yes 1.66 1.00-2.76 0.05
No 1
Peyronie’s disease present
Yes 1.26 0.53-3.03 0.60
No 1
Bilateral involvement
Yes 1.29 0.92-1.80 0.15
No 1
CI, confi dence interval; OR, odds rati o.
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The clinical characteristics that were statistically significant in this study are all 
features of the DD diathesis defined by Hueston9 and later revisited by Hindocha et 
al.2 In the revisited DD diathesis, the definition of ectopic lesions was restricted to 
the presence of knuckle pads.2 In our study, the presence of knuckle pads revealed 
the highest OR of all the significant clinical characteristics. Therefore, the presence 
of knuckle pads can be seen as the diathesis feature predominantly associated with a 
high genetic risk score.
Male sex and bilateral disease, 2 other DD diathesis features, were not associated 
with a high genetic score. The former can be easily explained, because the 9 DD sus-
ceptibility SNPs are not located on the sex chromosomes. Therefore, an analysis using 
these SNPs will not show differences related to sex. The latter we consider as a less 
specific characteristic, because bilateral disease occurs in many patients over time and 
the survey time point influenced this factor. Peyronie’s disease was also not associated 
with a high genetic score. In 36% of doctor’s questionnaires Peyronie’s disease was not 
scored (Table 2), perhaps because of hesitance of the doctor to ask about this issue. 
This might have had an effect on the results.
Table 5. Prediction of the significant diathesis features on high genetic risk score in an additional 
analysis using univariate logistic regression*
Variable OR 95% CI P-value
Age of onset
<50 1.92 1.18-3.12 0.009
≥ 50 1
Family history for DD
Positive 1.92 1.20-3.10 0.007
Negative 1
Knuckle pads present
Yes 4.40 1.76-10.98 0.001
No 1
Ledderhose’s disease present
Yes 1.44 0.59-3.51 0.42
No 1
CI, confidence interval; OR, odds ratio.
* For this additional analysis, the low genetic risk score group was defined as a wGRS lower than 
1 SD from the median and the high genetic risk score group as a wGRS higher than 1 SD from the 
median.
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The strengths of this study were the prospecti ve design and the large cohort of pa-
ti ents who have been characterized. Limitati ons of this study were the lack of follow-
up, the use of nonvalidated questi onnaires, and the fact that, in only 566 pati ents, the 
doctor’s questi onnaire was completed. Because pati ents presented to the outpati ent 
clinics for evaluati on of their disease, presumably because of concern of their condi-
ti on, there might have been a selecti on bias.
DD pati ents who present with an age of onset younger than 50 years, a positi ve fam-
ily history, or ectopic disease (parti cularly with knuckle pads) are more likely to carry 
more risk alleles for the discovered DD SNPs than pati ents without these diathesis 
features. It is reassuring to fi nd that there was a relati on between certain diathesis 
features and the recently identi fi ed DD risk genotypes.
We know that the diathesis features of DD can lead to a more aggressive disease. 
It is to be expected that the more risk alleles a pati ent carries (the higher the geneti c 
risk score), the more aggressive the disease will be. We are currently planning the 
follow-up for pati ents in this study to answer this questi on. It would be interesti ng 
to investi gate the relati onship between geneti cs and the course of the disease and 
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In this thesis we investi gated the geneti c background of Dupuytren’s disease (DD) 
and its associated fi bromatosis. Although DD has been recognized for centuries, its 
aeti ology and pathogenesis have not been fully elucidated. The clustering of DD seen 
in families, its prevalence in individuals of northern European descent, and its associa-
ti on with other fi bromatosis, like Peyronie’s disease (PD) and Ledderhose’s disease, 
suggest a geneti c infl uence on the development of this disease. Understanding the 
geneti c background of DD could provide insight into the pathogenesis of the disease. 
Geneti c knowledge about fi bromatosis could also aid in disease predicti on, facilitate 
diagnosis, lead to the development of alternati ve, non-surgical, treatments, and even 
to interventi ons that prevent fi bromatosis from occurring or re-occurring.
To this end, we have studied the mode of inheritance of familial DD and performed 
a genome-wide associati on study (GWAS). This resulted in the discovery of nine 
geneti c loci associated with DD that show strong evidence for the involvement of 
Wingless-type MMTV integrati on site family (Wnt) signaling in disease suscepti bility. 
Subsequent analysis of these suscepti bility loci provided evidence for a shared geneti c 
risk factor between DD and PD. Finally, we discovered that pati ents with certain DD 
diathesis features are more likely to carry more risk alleles for the DD single nucleoti de 
polymorphisms (SNPs) than pati ents without these clinical features. In the following 
discussion, we interpret what these results mean for disease predicti on, treatment 
and pathogenesis.
Disease prediction and the role of genetics
The current situation
Several clinical characteristi cs of pati ents with DD have been found to be related to a 
more aggressive course of the disease or diathesis and can be used to predict the pro-
gression of the disease. In 1963, Hueston postulated the DD diathesis and suggested 
that four factors are involved: early onset of disease, bilateral involvement, a positi ve 
family history, and the presence of ectopic lesions.1 In 2006, male gender was added as 
a diathesis factor, “early onset of disease” was refi ned to age of onset under 50 years, 
and the ectopic lesions were restricted to the presence of knuckle pads only.2 Features 
of the DD diathesis were also used in a scoring system by Abe et al. in 2004 to evaluate 
the risk of recurrence and extension of DD in a Japanese populati on who showed a 
more aggressive course of the disease.3 They suggested the additi on of radial side 
involvement and previous surgery to the litt le fi nger to the diathesis scoring list. In 
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chapter 6 of this thesis, we show that patients with an age of onset of DD younger than 
50 years, a family history positive for DD, knuckle pads and Ledderhose’s disease were 
more likely to carry more risk alleles for the nine DD SNPs we discovered (chapter 4) 
than patients without these diathesis features. The question remains whether these 
genetic variants can also help us with disease prediction.
Disease prediction in complex genetic disease
Complex genetic diseases such as DD result from the joint effects of multiple genetic 
factors, mostly with small effect sizes, and environmental factors. This is in contrast to 
monogenetic diseases where mutations in a single gene induce a disease or lead to a 
distinctively higher risk for that disease. Risk of a complex genetic disease differs only 
slightly between a carrier and a non-carrier of a risk variant of a single susceptibil-
ity gene. Hence, prediction of disease based on a single variant is not informative.4 
Prediction of complex diseases instead requires the simultaneous testing of multiple 
genetic variants known as genetic profiling. Furthermore, the value of this genetic pro-
filing depends on the heritability: the proportion of phenotypic variation in a disease 
that is due to genetic variation. Assuming that the heritability of a disease is 50% (a 
hypothetical assumption) and that all genetic variants affecting this trait are known 
and their effects can be estimated without error, genetic profiling would still predict 
only half of the phenotypic variation. To measure the efficacy of a disease predictor, 
whether genetic or clinical, the area under the receiver operator curve (AUC) is typi-
cally reported; a high AUC value means that there is high predictive power.
In a systematic review of risk prediction based on genetic markers in type 2 diabetes, 
the AUCs among the 23 studies included did not improve substantially with the addi-
tion of genetic markers compared to the conventional risk prediction based on clinical 
risk factors (median AUC 0.79 versus median AUC 0.78, respectively).5 In another study, 
the investigators used genetic risk reclassification for type 2 diabetes by age of onset 
(below or above 50 years) using 40 SNPs. In people younger than 50 years, the genetic 
risk score improved upon that from prediction based on clinical risk factors alone by 
10%, compared to 0.4% in people 50 years or older.6 This example shows that a more 
accurate risk classification can improve the predictive power of genetic markers when 
using them in an appropriate subgroup of individuals.
Since, for most complex diseases, the susceptibility loci discovered so far only 
explain a small proportion of the heritability, they consequently have low predictive 
power. It has been suggested that a substantial proportion of heritability comes from 
a large number of common SNPs, each with very small effect sizes, which, as a con-
sequence, cannot be detected at the stringent genome-wide significance levels with 




approach that includes many SNPs that do not reach genome-wide signifi cance.7 Stahl 
and colleagues esti mate that by using polygeneti c risk score analysis in type 2 diabetes, 
an additi onal 49% of disease risk can be explained.8 A similar eff ect is seen in studies 
on the quanti tati ve trait of height: in a large GWAS involving more than 100,000 sub-
jects, 200 loci were identi fi ed that explain only 10% of the variance.9 However, when 
another study simultaneously considered 294,831 common SNPs in predicti ng adult 
height, 45% of the variance could be explained.10 Therefore, a polygeneti c risk score 
approach could be more useful for disease predicti on in DD as well.
Heritability of DD
Litt le was known about the heritability of DD unti l recently, with just a few reports 
from family and twin studies.11-13 More recently, Capsti ck et al. calculated that nine 
loci account for 12.1% of the total heritability of DD, based on a sibling recurrence risk 
(λs) in the UK of 4.5.14,15 In their study, 47% of siblings of DD pati ents had DD compared 
with 10% of randomly selected siblings. In another study, λs for DD was 2.9.13 However, 
in this study, λs was calculated by dividing the sibling recurrence risk in DD pati ents 
(10.3) by the populati on prevalence of DD in north-western England (3.5). Since the 
reported prevalence of DD varies considerably, between 0.6% and 31.6%,16 one must 
be careful with the interpretati on of these data.
Another method of calculati ng the geneti c variance explained by the nine DD loci is 
to esti mate the populati on att ributable risk (the proporti on of cases that would not 
Table 1. The calculated populati on att ributable risk (PAR) for Dupuytren’s disease assuming a 
prevalence of the disease of 5%, 8% and 32%.







1 rs7524102 22571034 G/A 1.2 1.9 5.3
7 rs16879765 37955620 A/G 4.0 6.1 15.6
7 rs4730775 116704354 A/G 0.9 1.4 4.3
8 rs611744 109297184 G/A 1.4 2.2 6.5
8 rs2912522 70154934 G/A 1.4 2.3 6.9
9 rs10809650 1192371 G/A 0.9 1.5 4.4
19 rs11672517 62370006 A/G 1.5 2.3 6.7
20 rs8124695 38461850 A/C 1.8 2.8 7.7
22 rs6519955 44800506 A/C 2.1 3.3 9.5
PAR% combined 14.4 21.5 50.4
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occur if the factor where eliminated, PAR). However, PAR is also estimated based on 
prevalence. In Table 1, we calculated PAR for DD assuming a prevalence of the disease 
of 5%, 8% and 32%, resulting in a PAR of 14.4%, 21.5% and 50.4%, respectively. These 
prevalence numbers are based on a study in Flanders, where 32% of individuals with 
an age above 50 years had DD (at least one nodule) and 8% of individuals had a flexion 
contracture of the fingers.17 In a more recent prevalence study in the northern part 
of the Netherlands, a random sample of 1,360 individuals was investigated: in 17.9% 
of individuals of over 50 years of age, nodules and cords were present and 4.2% of 
individuals had flexion contractures of the fingers.18 What our calculations show is that 
there are still uncertainties as to how much of the genetic variance is explained by the 
known DD susceptibility loci.
Is disease prediction relevant for DD?
DD is not a life-threatening disease and there are no preventative measures as yet. 
Therefore, it could be argued that it is not healthcare’s highest priority to predict who 
will develop DD in the future. Nevertheless, for a clinician it remains difficult to accu-
rately predict the course of DD. In some patients the disease remains stable and does 
not progress into disabling flexion contractures.19 An intervention in these cases is not 
necessary. In other patients the disease can be very aggressive and a more extensive 
treatment may be appropriate,20 since the type of treatment influences the chance of 
recurrence of the disease. For example, Van Rijssen and colleagues reported a recur-
rence rate of 84.9% after five years for needle fasciotomy and of 20.9% for limited fas-
ciectomy.21 Since secondary surgery has more complications and a worse outcome,22 it 
would be helpful for the physician, and beneficial to patients, to accurately predict the 
course of the disease prior to deciding on the type of treatment.
How to further study and improve prediction in DD
Designing a prospective cohort study
In order to test if the currently-known genetic variation can be used for disease predic-
tion, a follow-up study of the probands included in the GWAS or a new prospective 
cohort study is desirable. LifeLines, a large, population-based, cohort study in the 
northern Netherlands,23 would be a suitable cohort for studying this topic. LifeLines 
aims to collect prospectively a wide spectrum of data from 165,000 individuals over a 
period of 30 years, to allow the longitudinal study of multiple diseases. DNA samples 
from more than 3,000 individuals from LifeLines were used as control individuals for 
the GWAS in chapter 4. Unfortunately for our study, DD had not been included as a 




of the hands and adding several questi ons to the current questi onnaires, in combina-
ti on with the already available geneti c data, would make this an ideal cohort to study 
disease progression and the relati on with geneti cs. In the light of the current digital 
and mobile era, we could even ask LifeLines parti cipants to photograph their hands 
and upload these to their private LifeLines folder. Additi onally, the LifeLines cohort 
could also be used for studying DD prevalence, and investi gati ng the relati onship of 
certain comorbiditi es and medicati on with the disease.
Finding more genetic variation involved in DD
Increasing sample size
As explained above, the ability to predict the course of DD will increase as we identi fy 
more of the geneti c variati on involved in the disease. To date, only one medium-
sized GWAS on DD has been performed that discovered nine loci associated with DD 
(chapter 4). For PD, we are just at the beginning of geneti c studies, with only our 
small associati on study revealing a shared DD locus at WNT2 (chapter 5). By increasing 
sample size, and thereby stati sti cal power, future GWAS should identi fy more geneti c 
associati ons. Since large numbers of SNPs are being tested in GWAS, an associati on 
must reach a stringent threshold (P < 5 x 10-8) to achieve stati sti cal signifi cance.24 Most 
GWAS are underpowered to identi fy signifi cant SNPs with smaller eff ect sizes. From 
recent studies we know that increasing the sample size has led to the discovery of 
many more common variants with modest eff ects in complex diseases.9,25,26 A study 
by Parkes and colleagues showed a strong relati onship between sample size and the 
expected number of detectable associated loci (r2 = 0.94).27.
To give an example of the sample sizes used in GWAS: the fi rst study in 2005, in 
more than 1,000 individuals with infl ammatory bowel disease (IBD), found only one 
associated locus.28 A large GWAS meta-analysis in 2011, in almost 45,000 individu-
als, revealed 99 IBD loci,29 and the most recent, even larger, meta-analysis in 75,000 
individuals identi fi ed 163 IBD loci.30
The Oxford team who collaborated with us in the replicati on phase of our DD 
GWAS (chapter 4) is currently building an extensive new cohort including more than 
5,000 cases for a larger second generati on GWAS in DD. Since we too are conti nuing 
to collect blood samples of DD pati ents, we will be able to contribute to the further 
expansion of future GWAS studies. Combining data from individual associati on studies 
in a meta-analysis increases the power to fi nd SNP associati ons for common alleles 
of modest eff ect size. However, diff erent studies may have been executed on diff er-
ent array platf orms and using diff erent numbers of SNPs. A useful tool to harmonize 
GWAS datasets for meta-analysis is imputati on. This technique is used to predict the 
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genotypes at SNPs that are not directly genotyped in the study sample, but based on 
existing knowledge of haplotype structure, such as from HapMap or the Genome of 
the Netherlands.31,32 Imputation can improve the power for GWAS in a single study,33 
and can be instrumental in the meta-analysis of GWAS as it facilitates combining data 
from different studies and/or different genotyping platforms. On the other hand, 
imputing genotypes can also introduce errors in the dataset depending on the qual-
ity of the reference genome and the linkage disequilibrium between genotyped and 
predicted SNPs.
Another approach to gaining power for GWAS would be to perform a cross disease 
meta-analysis, using diseases with a presumed similar background. In the case of DD 
this could, for instance, be another type of fibromatosis or other diseases in which a 
potential role for Wnt-signaling has been identified (for instance in colon cancer34). 
Such an approach has been successful for other complex human traits: in a meta-
analysis of celiac disease and rheumatoid arthritis GWAS studies identified 14 new 
shared disease loci.35
Selecting SNPs in a pathway
Instead of hypothesis-free testing of genetic markers for association, an alternative op-
tion is to use a candidate-pathway approach that consists of genes encoding proteins 
that are known to form a functional network.36 Only testing genes in a pre-defined 
pathway seriously decreases the number of markers to be used, and consequently the 
number of tests to be carried out, thereby reducing the need for statistical correction. 
The disadvantage of this kind of approach is its reliance on existing knowledge about 
the known or presumed biology of the phenotype under investigation. For DD it would 
be interesting to use this pathway approach for genes involved in Wnt-signaling. A 
Wnt-signaling pathway-association-analysis was recently performed in HCV-infected 
patients.37 They identified 58 candidate genes involved in the Wnt-signaling pathway 
and found 3,016 SNPs with a minor allele frequency (MAF) > 0.05 on the Illumina 
HumanOmni chip to be used for this analysis. Polymorphisms in several genes involved 
in the Wnt-signaling pathway were associated with hepatic fibrosis or inflammation 
risk in HCV-infected patients.
Low frequency and rare variants
Part of the genetic susceptibility for DD could be explained by variants with low MAF, 
defined as 0.5% < MAF < 5%, or by rare variants (MAF < 0.5%).38 These rare variants are 
not present on many of the commercially available GWAS chips (e.g. the chip we used 
for the DD GWAS), which mainly consist of variants with MAF greater than 5%. Due to 




to gain enough power to fi nd signifi cant associati on, e.g. more than 10,000 cases are 
needed to generate the 80% stati sti cal power necessary to detect a variant with a MAF 
of 0.1% and odds rati o of 2 (disease prevalence 0.05).39 On the other hand, the eff ect 
sizes of these rare variants are oft en not suffi  cient to be detected via classical linkage 
analysis in family studies (Figure 1, lower left ). Figure 1 shows the relati on between 
MAF and eff ect size; the lower the frequency of a geneti c variant, the higher the eff ect 
size. We performed linkage analysis (unpublished data) in six families (including the 
families described in chapter 3). In all, we investi gated 32 aff ected individuals and 
found no signifi cant linkage. Nor could we replicate the locus on 16q identi fi ed using 
linkage analysis in one large Swedish family by Hu et al.11 The fact that we did not fi nd 
signifi cant linkage could be the result of the lack of multi generati onal data. Since DD 
is a late onset disease, with a mean age of onset of 49 years in pati ents with a positi ve 
history of DD,13 it is diffi  cult to fi nd families where more than two generati ons are af-
fected. Other explanati ons could be lack of power or extensive geneti c heterogeneity.
The most comprehensive technique for detecti ng rare sequence variants is by 
sequencing (the process of determining the full nucleoti de order of a given DNA seg-
ment). Recently, the possibility of high-resoluti on high-throughput sequencing of a 
Figure 1. Feasibility of identi fying geneti c variants by risk allele frequency and strength of 
geneti c eﬀ ect (odds rati o). Reprinted by permission from Macmillan Publishers Ltd: [Nature] 
(Manolio et al.), copyright (2009).38
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whole exome, or even a whole genome, has become financially feasible. Sequencing 
studies on, for instance, IBD have identified multiple rare variants.40,41 However, Hunt 
and colleagues concluded from their large sequencing study of 25 GWAS risk genes of 
auto-immune diseases in 24,892 cases and 17,019 controls that rare variants have a 
minor role in disease susceptibility.42 It has been postulated that the remaining heri-
tability results from many common variant loci of weak effect in type 2 diabetes and 
autoimmune diseases.8,42-44
Structural variation and other interactions
Structural variation, such as copy number variants (CNVs, insertions and deletions) 
and copy neutral variation (inversions and translocations) could also account for a part 
of the unexplained heritability. CNVs can be detected using commercially available 
SNP genotyping arrays, however they are often under-represented.45 Shih et al. made 
the first attempts to find CNVs in DD and found significantly higher copy numbers of 
CNVs at chromosome 7p14.1 and 14q11.2.46,47 The strongest associated SNP in the DD 
GWAS (rs16879765; P = 5.6×10−39; odds ratio, 1.98) near SFRP4 is located at chromo-
some 7p14.1.
The missing heritability could also be explained by de novo mutations, epigenetic 
effects and gene-environmental interactions.
In contrast to DD patients with a positive family history for DD, we also see many 
sporadic cases, which could be caused by de novo mutation events rather than inher-
ited variants. De novo mutations in DD could be identified by sequencing exomes of 
sporadic DD patients and their unaffected parents and by investigating whether de 
novo mutations affecting protein sequences occur at higher than expected rates. It 
would be interesting to see if these mutations implicate genes in specific biological 
processes, as done by a study in schizophrenia, which found de novo mutations in 
genes encoding postsynaptic proteins.48
Epigenetic effects are reversible, heritable changes to the way cells respond to 
environmental cues and regulate gene expression. Epigenetic effects occur without 
changing the DNA sequence itself. The partially reversible process of switching part 
of the genome on or off is controlled by DNA methylation, histone modification, RNA 
interference and chromatin structure. The Encyclopaedia of DNA Elements (ENCODE) 
project has systematically mapped these regions of the genome.49 It is not yet known 
if these epigenetic effects are tissue-specific and therefore it is not clear how these 
effects should be investigated in DD.
For the investigation of gene-environmental interactions very large sample sizes are 
typically needed to generate adequate power to perform the analysis while taking into 




to investi gate these interacti ons. DD is known to be associated with factors such as 
smoking, use of alcohol, anti -epilepsy drugs, and medical conditi ons including liver 
disease and diabetes.18,50,51
The role of genetics in the treatment of DD
The current situation
The standard treatment of DD consists of surgical excision of the nodules and cords, 
collagenase injecti on, or percutaneous division.21,52 At present, the disease is incurable 
and recurrence rates following treatment vary from 8% to 85%, depending on the 
treatment modality and defi niti on of recurrence.20,21,53,54 At the moment, there is no 
medicati on available to treat for DD.
Treatments based on genetic knowledge
Geneti c knowledge could be helpful in developing new treatment strategies for 
disease. Some GWAS fi ndings have identi fi ed previously unknown pathogenic path-
ways, such as complement-mediated infl ammati on in macular degenerati on55 and 
autophagy in Crohn’s disease.56 Clinical applicati ons to interact with these pathways 
in these diseases sti ll have to be developed. In the DD GWAS (chapter 4), we identi -
fi ed nine genome-wide signifi cant loci for DD. At six of these loci, genes involved in 
Wnt-signaling are present. It is important to note that thus far we have only identi fi ed 
genome-wide signifi cant associati ons with SNPs near WNT genes. We did not formally 
prove that Wnt-signaling is involved in DD.
Wnt-signaling is also a criti cal regulatory component in the control of bone forma-
ti on and bone resorpti on. WNT induces osteoblastogenesis and thereby enhances 
bone formati on and suppresses osteoclastogenesis. This evidence forms the basis for 
new anabolic approaches to the treatment of osteoporosis.57 Anti bodies to sclerosti n, 
which prevent the binding of sclerosti n to the Lrp-5-Lrp6-co-receptor, enhance Wnt-
signaling and increase bone mass in rodent and in non-human primates.58 Clinical 
trials with romosozumab (AMG 785), a monoclonal humanized anti body to sclerosti n 
are currently underway.59 Anti -Dkk-1 anti bodies that sti mulate Wnt-signaling have also 
been developed for human use. Informati on on their tolerability and eff ecti veness is 
not available yet.60 These drugs that infl uence Wnt-signaling could also have an eff ect 
on DD, and could potenti ally be used in its treatment.
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Drug targets for DD
At the moment, more information is needed about the presumed role of Wnt-signaling 
in DD. Investigation of the downstream effects of the associated DD loci are needed. 
Also, the identification of new genetic variants and the pathways involved may provide 
new drug targets for DD. In a recent paper on rheumatoid arthritis (RA), the investiga-
tors found 98 RA risk genes, 27 of these genes are the pharmacological targets of 
known and approved RA drugs.61
It would be interesting to know if there are also patients with DD in the romosozumab 
drug trial. The potential effect on DD could then simultaneously be investigated. The 
incidence of DD in individuals treated with WNT drugs could potentially be lower and 
individuals with DD could have a less aggressive phenotype.
The role of genetics in the pathogenesis of DD
The current situation
The pathogenesis of DD remains uncertain. The proliferating myofibroblasts are the 
cells thought to be responsible for the flexion contraction in DD.62,63 These cells are 
characterized by the presence of α-smooth muscle actin, an actin isoform typical of 
vascular smooth muscle cells.64 Transforming growth factor (TGF)-ß is an important 
factor involved in the development of myofibroblasts and also promotes collagen 
formation, with a decrease of the ratio of type III to type I collagen.65
Insight in pathogenesis based on genetic findings
As already mentioned, genetic associations can yield insight into previously unknown 
pathogenic pathways, such as complement-mediated inflammation in macular degen-
eration55 and autophagy in Crohn’s disease.56 The GWAS findings in DD (chapter 4) 
highlighted Wnt-signaling as a possible pathway involved in DD pathogenesis. It must 
be noted that in the light of all the GWAS performed since 2005, it is a unique finding 
to discover such a clear pathway in a single moderately powered GWAS.
The WNT gene family is an essential mediator in the cell-cell communication dur-
ing embryogenesis.66 It consists of structurally related, highly conserved genes that 
encode glycoproteins, which have a function as extracellular signaling molecules. 
The best-known Wnt-signaling pathway is the canonical pathway, which activates the 
nuclear functions of ß-catenin, leading to changes in gene expression that influence 
cell proliferation and cell survival.67
Abnormal Wnt-signaling has also been linked to a range of other diseases such as 




osteoporosis,75 and fi bromatosis.67,76 Except for the associati ons of DD with other 
fi bromatosis, liver disease and diabetes,51 no other comorbiditi es are yet known. It 
would be interesti ng to investi gate if DD is more common in pati ents with one of the 
above diseases also linked to abnormal Wnt-signaling.
Most of our knowledge is derived from studies of cancer. In colon cancer, up-regu-
lati on of Wnt-signaling causes intesti nal crypt cells to proliferate for longer than usual 
before they migrate and diff erenti ate.34 This prolonged proliferati on phase results in 
the formati on of polyps and can predispose to cancer. Abnormal proliferati on of myo-
fi broblasts/fi broblasts is a key feature in the early development of DD77 and therefore 
fi ts well with our current ideas of the origin of the disease. An imbalance of Wnt-
signaling in DD could cause fi broblasts in the hand to proliferate and form nodules.
Translation into function
Att empts should be made to proceed from disease-associated SNPs to functi on. By 
identi fying downstream eff ects, more insight will be gained into DD’s pathogenesis.
In GWAS, associati ons are found with common variants, which are generally not the 
disease-causing variant. A follow-up approach would be to search for disease-causing 
variants, which could be done by DNA sequencing. Sequencing of aff ected individuals 
in families with DD or pati ents with extreme phenotypes would maximize the chances 
of positi ve results.
Limiti ng the sequencing eff ort to a limited target region opti mizes effi  ciency and 
cost-eff ecti veness. We could start with the loci that were pinpointed by the GWAS 
in DD or prioriti ze on candidate genes in these loci. Genes can be prioriti zed based 
on known gene characteristi cs, however, we tend to prefer genes and pathways with 
parti cular functi ons that connect to the disease in questi on. There are also tools avail-
able to prioriti ze genes in an associated LD block, such as GRAIL (Gene Relati onships 
Across Implicated Loci), which is based on text-mining.78 There are multi ple other ways 
to prioriti ze genes, for example, in a recent paper on rheumatoid arthriti s, genes were 
prioriti zed based on eight criteria.61
Based on our fi ndings in chapter 4, I would suggest focusing on the WNT gene 
members at the loci discovered. An interesti ng candidate gene at the non-WNT con-
taining loci is MAFB on 20q. In a study by Lee et al. RNA of MAFB was shown to be 
up-regulated in excised cord ti ssue from persons with DD, compared with fascia of the 
hands in healthy controls.79 When they used immunochemistry staining, MAFB protein 
was only identi fi ed in DD ti ssue and not in the fascia of healthy controls, implicati ng a 
possible role in DD development.
Another opti on to gain more insight into downstream aff ects would be to investi gate 
expression quanti tati ve trait loci (eQTL) for DD. These are loci at which geneti c al-
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lelic variation is associated with variation in certain gene expression levels. Studies on 
eQTLs have shown that common variants can affect gene expression levels of nearby 
genes (cis eQTLs)80 and also of genes further away (trans eQTLs).81,82
Differential gene expression studies could also help in dissecting disease pathogen-
esis. Obviously, for DD these studies should be performed in the DD tissue itself. The 
most cell-rich tissue is found in the nodule in comparison to cord tissue.65 The cell 
type known to be involved in DD is the myofibroblast/fibroblast.83,84 As control tissue, 
the transverse palmar ligament85,86 (Skoog’s fibres) or the A1 pulley have been used, 
since these are not involved in DD. Samples of DD tissue are easily available, since the 
treatment of DD consists of excision of the affected tissue. However, direct isolation 
of RNA from DD tissue has proven to be very difficult in our experience. An alternative 
is to culture cells from DD tissue and subsequently isolate RNA out of these cells. The 
next step is to study the protein, the end product of a gene. It is currently possible to 
selectively knock out a gene in a cell by using the bacterial clustered regularly inter-
spaced short palindromic repeats (CRISPR)-Cas9 system.87 Investigating the properties 
of myofibroblast/fibroblast with selective knock out of one of the WNT genes could 
yield more insight into the Wnt-signaling pathway and the function of Wnt proteins 
in DD.
In summary
Our results have shown that DD is a complex disorder with genetic factors playing an 
important role in disease susceptibility. This new insight provides avenues for addi-
tional research into the molecular basis of DD and the associated fibromatosis. Below 
we have outlined several ways to continue this mission:
- Designing a prospective cohort study to investigate how disease progression is 
related to the DD susceptibility SNPs and investigate gene-environmental interac-
tions
- Identifying more common variants using a larger second-generation GWAS, meta-
analysis with future GWAS studies or a candidate-pathway approach; expanding 
the genetic studies to include structural variations (CNV) analysis
- Identifying rare variants using (exome) sequencing techniques or linkage analysis in 
multigenerational families
- Performing functional studies in cell lines of fibroblasts/myofibroblasts that focus 




With the research presented in this thesis we have made a large leap forward in the 
geneti c studies of DD. However, there is sti ll a lot of work to do to completely dissect 
the origin of DD. In our department, and in collaborati on with the Departments of 
Medical Geneti cs (Groningen and Los Angeles) and Molecular Biology (Groningen), 
we are working on the perspecti ves discussed above. These future studies have the 
potenti al to make personalised medicine possible and to improve the clinical care of 
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Dupuytren’s disease (DD) has been recognized for centuries, but its aeti ology and 
pathogenesis has not been fully elucidated. The clustering of DD in families, its 
prevalence in individuals of northern European descent, and its associati on with other 
fi bromatoses (Peyronie’s disease (PD) and Ledderhose’s disease) suggest a geneti c 
infl uence on the development of this disease. The general aim of this thesis was to 
investi gate the geneti c background of DD and its associated fi bromatosis. This know-
ledge could lead to a bett er understanding of the disease and might ulti mately lead to 
alternati ve treatments.
First, an introducti on is given into basic geneti c principles and an overview of the 
pre-existi ng geneti c knowledge of Dupuytren’s disease is provided.
Then we studied the mode of inheritance of familial DD, for which we analysed the 
pedigrees of 11 families, consisti ng of 475 family members and 66 pati ents. We con-
fi rmed the work of previous studies and showed that the mode of inheritance was 
most compati ble with an autosomal dominant mode of inheritance for a late onset 
disease with variable penetrance. However, the inheritance did not completely fol-
low the patt ern of a Mendelian disease and we therefore hypothesized that DD is a 
complex geneti c disease infl uenced by a combinati on of common geneti c variants and 
environmental factors.
In order to identi fy common geneti c variants associated with this disease, we carried 
out a genome-wide associati on study (GWAS), in which we initi ally analysed 234,939 
single nucleoti de polymorphisms (SNPs) in 856 pati ents with DD and 2,836 controls. 
We identi fi ed eight SNPs at three loci that had genome-wide signifi cance. Tests of 
replicati on and a further joint analysis of 2,325 pati ents with DD and 11,562 control 
individuals from three diff erent populati ons yielded genome-wide signifi cant associa-
ti ons with eleven SNPs at nine diff erent loci. Six of these loci contain genes known 
to be involved in the Wnt-signaling pathway, suggesti ng that abnormaliti es in this 
pathway are key to the process of fi bromatosis in DD.
Given the clinical overlap between DD and PD, we then examined if the nine DD sus-
cepti bility loci were also involved in PD, by genotyping 111 pati ents with PD and 490 
controls. We found a signifi cant associati on at one of the DD suscepti bility loci (WNT2 
locus), thus providing evidence that PD and DD share some geneti c suscepti bility 
factors. We did not fi nd any evidence for involvement of the SFRP4 locus (the most 
strongly associated locus with DD) with PD, despite having stati sti cal power of 98% 
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based on previous DD findings. Our result implies that the two diseases could also 
have some distinct genetic susceptibility factors.
Finally, we investigated if there was an association between the clinical characteristics 
of patients with DD and their genetic risk score (based on the nine SNPs identified). We 
analysed the genetic and clinical data of 933 patients. They were categorized into high 
and low risk groups, according to their weighted genetic risk score. We used logistic 
regression to study the association of clinical characteristics with a high genetic risk 
score and found that patients with DD who present with a young age of onset (<50 
years) and a positive family history for DD, Ledderhose’s disease, or knuckle pads were 
likely to carry more risk alleles for our nine SNPs than patients without these diathesis 
features.
The research work in this thesis represents a major leap forward in the study of the 
genetics of DD. However, there is still a lot of work needed to fully dissect the origin 
of DD.
Future studies include a larger second-generation GWAS to identify more common 
variants, and also studies aimed to find rare variants and structural variations. A 
prospective cohort study could be designed in order to investigate the relationship 
between disease progression and genetic variation and to study gene-environmental 
interactions. Furthermore, functional studies are needed to investigate how these 
genetic variants influence protein function.
These future studies may lead to improved clinical care, to a more personalised 
treatment and, ultimately, to a cure for Dupuytren’s disease.
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De ziekte van Dupuytren is een aandoening, waarbij zich bindweefsel vormt (fi bro-
matose) in de handpalm en vingers. Dit kan leiden tot een kromstand van de vingers. 
De ziekte van Dupuytren is eeuwen geleden voor het eerst beschreven. Echter, de 
ontstaanswijze is nog steeds niet goed bekend. De ziekte komt veel in families voor 
en wordt vooral gezien bij mensen van Noord-Europese afk omst. Tevens zien we 
de ziekte van Dupuytren vaker samen met vergelijkbare fi bromatosen op andere 
lichaamsdelen (de ziekte van Peyronie in de penis en de ziekte van Ledderhose in 
de voet). Bovenstaande kenmerken suggereren een geneti sche achtergrond voor de 
ziekte van Dupuytren en vergelijkbare fi bromatosen.
Het voornaamste doel van dit proefschrift  was het onderzoeken van de geneti sche 
achtergrond van de ziekte van Dupuytren en vergelijkbare fi bromatosen. Deze kennis 
zou kunnen leiden tot een beter begrip van de ziekte en dit zou uiteindelijk kunnen 
resulteren in nieuwe behandelingen.
In dit proefschrift  wordt eerst een introducti e gegeven over de basis principes van de 
geneti ca en er wordt een overzicht gegeven van de aanwezige geneti sche kennis van 
de ziekte van Dupuytren.
Vervolgens werd de manier van overerven onderzocht in families waar de ziekte van 
Dupuytren voorkomt. Elf families bestaande uit 475 familieleden en 66 pati ënten wer-
den onderzocht. De manier van overerven kwam overeen met hetgeen voorgaande 
onderzoekers hadden geconcludeerd: een autosomaal dominante overerving. Dit be-
tekent dat één van de ouders de aandoening kan doorgeven aan gemiddeld de helft  van 
de kinderen. Echter, de overerving paste niet geheel in dit patroon en derhalve werd 
verondersteld dat de ziekte van Dupuytren mogelijk veroorzaakt zou kunnen worden 
door het samenspel van vele genen die elk een klein risico met zich mee brengen in 
combinati e met omgevingsfactoren. Men noemt dit een complex geneti sche ziekte.
Om te onderzoeken of er meerdere genen betrokken zijn bij het ontstaan van de ziekte 
werd een zogeheten associati e studie uitgevoerd, waarbij 234.939 gen-varianten 
onderzocht werden in 856 pati ënten en 2.836 controle personen. Er werden acht gen-
varianten gevonden verspreid over drie locati es, die geassocieerd zijn met de ziekte 
van Dupuytren. Daarna werd een vervolg studie gedaan in 2.325 pati ënten en 11.562 
controle personen afk omsti g uit drie verschillende populati es (Nederland, Engeland 
en Duitsland). Gezamenlijke analyse van al deze gegevens leverde elf gen-varianten op 
in negen verschillende geneti sche  locati es. Zes van deze locati es bevatt en genen die 
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betrokken zijn bij de zogenaamde Wnt-signalering. Dit suggereert dat afwijkingen in 
deze groep van genen een belangrijke rol spelen bij de ziekte van Dupuytren.
Gezien de klinische overlap tussen de ziekte van Dupuytren en de ziekte van Peyronie, 
onderzochten we of de negen geïdentificeerde gen-varianten ook een rol spelen bij 
de ziekte van Peyronie. Hiervoor werden 111 patiënten en 490 controle personen 
onderzocht. Eén van de gen-varianten (gelegen bij het WNT2 gen) was eveneens geas-
socieerd met de ziekte van Peyronie. Deze bevinding levert bewijs voor een overlap in 
de genetische gevoeligheid voor deze ziektes. 
Tenslotte hebben we onderzocht of er een relatie bestaat tussen klinische kenmerken 
van patiënten met de ziekte van Dupuytren en hun genetische score. Deze genetische 
score is gebaseerd op de negen geïdentificeerde gen-varianten en is als het ware 
een optelsom van de gen-varianten, die een individuele patiënt bij zich draagt. Dus 
hoe meer van deze varianten je hebt, hoe hoger je genetische score. We hebben de 
genetische en klinische gegevens van 933 patiënten geanalyseerd. Hierbij vonden we 
dat patiënten met de ziekte van Dupuytren met de volgende kenmerken: aanvang van 
de ziekte voor het vijftigste levensjaar, bloedverwanten met de ziekte, de ziekte van 
Ledderhose of  ‘knuckle pads’ (knobbels op de strekzijde van de vingers) een hogere 
genetische score hadden. 
Met de studies in dit proefschrift is een grote stap gemaakt in het onderzoek naar de 
genetica van de ziekte van Dupuytren. Echter, er is nog een hoop werk te doen om de 
exacte ontstaanswijze te achterhalen.
Toekomstig onderzoek kan bestaan uit een grotere tweede generatie associatie stu-
die, waarbij ook naar andere soorten gen-varianten gekeken kan worden. Verder zou 
een studie uitgevoerd kunnen worden, waarbij patiënten in de tijd gevolgd worden 
en de relatie tussen de voortgang van de ziekte en de aanwezige gen-varianten en 
omgevingsfactoren wordt bekeken. Tevens is er onderzoek nodig naar de effecten van 
de geïdentificeerde gen-varianten op de functie van de uiteindelijke eiwitten en cellen.
Deze toekomstige onderzoeken zouden kunnen leiden tot een verbeterde, geper-










Het is alweer ruim 7 jaar geleden dat ik begon met mijn promotie onderzoek in het 
kader van een AGIKO constructie (gecombineerde opleiding tot medisch specialist en 
promotie onderzoek). Na 2 jaar als ANIOS plastische chirurgie in het Catharina zie-
kenhuis te Eindhoven gewerkt te hebben, ging ik solliciteren voor een opleidingsplek 
plastische chirurgie in het Universitair Medisch Centrum Groningen. Echter tijdens het 
gesprek bleek het om een zogenaamde AGIKO plek te gaan. Na een korte aarzeling 
besloot ik om deze mogelijkheid met beide handen aan te pakken.
Het team bestond uit Prof. dr. Paul Werker, Prof. dr. Roel Ophoff, Prof. dr. Cisca 
Wijmenga en ik. Roel en Paul hadden elkaar ontmoet op een internationaal congres 
en daar was het idee ontstaan om een genetische studie op te gaan zetten naar de 
ziekte van Dupuytren. Bij Roel zit de ziekte van Dupuytren in de familie en Paul heeft 
een grote expertise in de behandeling van de ziekte van Dupuytren. Cisca was net 
benoemd als hoofd van de afdeling genetica in het UMCG en was bereid om mee te 
werken aan het project.
Prof. dr. Werker, beste Paul, ik bewonder jouw energie en passie voor ons vak en 
natuurlijk de ziekte van Dupuytren. Ik wil je bedanken voor het vertrouwen dat je in 
mij had om dit grote project van de grond te krijgen. Tijdens onze vele gesprekken 
wist je mij altijd te stimuleren en was je altijd eerlijk en recht door zee. Genetica was 
voor ons beiden een onbekend gebied, dankzij de onmisbare expertise van onze top-
genetici zijn we een heel eind gekomen. Onze uitstapjes naar het buitenland waren 
erg plezierig.
Prof. dr. Ophoff, beste Roel, ik wil je bedanken als initiator van het project. Ik heb je 
ervaren als een integer persoon en ik heb het idee dat we vaak op een lijn zaten. Onze 
long distance-samenwerking werd mogelijk gemaakt door Skype en onze Macbooks, 
hierdoor leek Utrecht en zelfs Los Angeles dichtbij. 
Prof. dr. Wijmenga, beste Cisca, jij zette hoog in voor de genoomwijde associatie stu-
die, minstens 1000 patiënten moesten verzameld worden. Het was een zeer ambitieus 
plan. Ik heb van jou geleerd dat je groot moet denken als je iets wilt bereiken. Dankzij 
jou en de knappe koppen op jouw afdeling heb ik mij een deel van de genetica eigen 
kunnen maken. 
De leescommissie bestaande uit Prof. dr. de Bakker, Prof. dr. Hovius en Prof. dr. Snieder, 
hartelijk dank voor het beoordelen van dit proefschrift.
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Beste Eric en Esther, ik werd altijd welkom ontvangen in het lab in Utrecht. We heb-
ben samen van alles uitgeprobeerd om het stugge Dupuytren weefsel klein te krijgen, 
zodat we hieruit RNA en DNA konden isoleren. Het bleef tot het einde toe lastig en 
vaak frustrerend. Ik wil jullie bedanken voor jullie hulp en natuurlijk de gezelligheid.
Beste Kristel, we hebben vaak gebrainstormd over de Linkage studie, helaas hebben 
we deze studie nog niet kunnen publiceren. Ik wil je bedanken voor de analyses die je 
hebt uitgevoerd en wens je veel succes met jouw onderzoek.
Beste Monique en Ron, bedankt voor jullie goede hulp. Monique heeft me de kneepjes 
van het DNA isoleren bijgebracht en later kwam ik je weer tegen als operatieassistent. 
Ron heeft mij begeleid bij het isoleren van meer dan 1500 samples, wat een karwei! 
Beste Marcel, Mathieu en Soesma, bedankt voor jullie hulp. Marcel en Mathieu waren 
betrokken bij het opzetten van de logistiek van de studie. En later kwam ik Marcel weer 
tegen bij LifeLines. Mathieu, als ik ook maar iets nodig had in het lab kon ik altijd bij 
jou terecht. Bedankt hiervoor. Soesma, bedankt voor het hybridiseren van de samples, 
deze klus had ik zelf niet kunnen klaren.
Beste Pieter, bedankt voor je goede hulp in het lab. Wat had ik zonder jou en je robot 
gemoeten.
Dear Gosia, Asia and Jihane, thank you for your help with the genetic analysis; using 
PLINK, R-package and performing genetic risk scoring. Good luck with your scientific 
carriers.
Beste Noortje, bedankt voor je hulp bij onder andere de ‘principal component’ ana-
lyse. Ik vond het plezierig om een medestander te hebben als clinicus op de genetica 
afdeling.
Beste Harm-Jan, bedankt voor de hulp bij de imputatie van de GWAS en ook de uitleg 
in de bio-informatica. Succes in Boston!
Beste Lude, ik wil je graag bedanken voor alle overleg momenten. Met name jouw 
steun en hulp tijdens de NEJM rebuttal fase is heel waardevol geweest.
Beste Cleo, bedankt voor je hulp met name in de laatste fase van mijn promotie.
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Dankwoord
Beste Jacky, ik heb het als een ontzettende luxe ervaren dat mijn teksten door jou 
ge-edit zijn. Hartelijk dank hiervoor.
I would like to thank all the other people from the celiac group and genetic department 
who have been involved in this project.
Beste Jitske, je was een van de eerste studenten betrokken bij het genetisch Dupuytren 
onderzoek. Jij bent onder andere druk bezig geweest om families met Dupuytren uit te 
pluizen. Bedankt voor je goede werk.
Hanna, Nirvana en Sterre, beste dames, zonder jullie geweldige ondersteuning was het 
nooit gelukt om de administratie van zo’n groot project te verwerken. Hartelijk dank 
voor jullie hulp.
Beste Freek, bedankt voor het digitaliseren van het merendeel van de vragenlijsten. 
Jammer dat het niet gelukt is om samen tot een publicatie te komen.
Graag wil ik alle collega’s bedanken, die betrokken zijn geweest bij het includeren van 
Dupuytren patiënten. Zonder jullie was het allemaal niet mogelijk geweest!!!
Apart wil ik graag de contactpersonen noemen van de externe klinieken: Auke de 
Boer en Marius Kemler (Martini Ziekenhuis), Hein ter Linden (Isala klinieken),  Anneke 
Knepper (Medisch Centrum Leeuwarden), Oliver Zöphel (Medisch Spectrum Twente), 
Maarten Hoogbergen en Luitzen de Boer (Catharina Ziekenhuis).
Dear Hans Hennies and Dominic Furniss, thank you for collaborating with us on the 
GWAS. By working together, we were able to make our study so successful! I hope we 
can continue our cooperation.
Dr. van Driel, beste Mels, ik wil je graag hartelijk bedanken voor de enthousiaste me-
dewerking aan de Peyronie studie! De inclusie van al deze patiënten is volledig aan jou 
te danken.
Prof. dr. van der Sluis, beste Corry, graag wil ik je hartelijk bedanken voor het uitvoeren 
van de belangrijke taak als onafhankelijk arts binnen het GODDAF onderzoek. Deze 
functie is een stuk drukker gebleken dan ik aanvankelijk voor ogen had.
Graag wil ik het LifeLines team ruimhartig bedanken voor de samenwerking! Zonder 
het gebruik van de LifeLines data als controles hadden we de GWAS niet kunnen uit-
voeren. Ik hoop dat we in de toekomst verder kunnen samenwerken. In hoofdstuk 7 
(general discussion) zijn een aantal voorbeelden voor toekomstig onderzoek gegeven.
Beste Evert-Jan, graag wil ik je bedanken voor je hulp bij mijn onderzoek en met name 
bij het maken van prachtige illustraties en flitsende keynote presentaties. Je geeft nu 
vervolg aan het genetisch Dupuytren onderzoek. Ik ben erg benieuwd naar de resulta-
ten en wens je veel succes!
Beste Tim Hoffman, met veel enthousiasme begon je aan functionele studies als ver-
volg op mijn onderzoek. Helaas heb je dit door omstandigheden niet af kunnen maken. 
Ik wil je hartelijk danken voor de grote hulp bij het maken van de illustraties voor de 
kaft van dit proefschrift.
Beste Bert Tebbes en Judith Bender, hartelijk dank voor alle foto’s die jullie gemaakt 
hebben van de Dupuytren patiënten. Zie ook de prachtige opname die gebruikt is voor 
de kaft.
Ik wil alle Dupuytren patiënten die wilden deelnemen aan het onderzoek bedanken 
voor de medewerking.
Beste Hildo, de vele overleg momenten en ook dart sessies werkten heel relativerend, 
hiervoor wil ik je bedanken. Ik wens jou veel succes met de afronding van je eigen 
proefschrift en hoop dat we in de toekomst goed contact houden.
Mede AIOS plastische chirurgie: Steven, Vic, Patrick, Marijn, Mireille, Johan, Ellen, 
Ilona, Rinze en Merel. Bedankt voor de fijne samenwerking.
Beste mede onderzoekers plastische chirurgie: Rinze, Johan, Evert-Jan, Ellen, Rosanne, 
Dieuwke en Anna. Bedankt voor de gezelligheid en de vele thee momenten. Succes 
met jullie onderzoek!
Collega’s van de afdeling plastische chirurgie in het UMCG. Alle secretaresses, me-
dewerkers, verpleegkundigen en artsen wil ik bedanken voor de jarenlange goede 
samenwerking.




En niet onbelangrijk qua productiviteit wil ik Apple (Steve Jobs) bedanken voor het 
ontwikkelen van zo’n fijne spullen.
Mijn paranimfen. Wat ben ik blij dat jullie mij vandaag bij willen staan.
Lieve Merel, we hebben heel wat overleg momenten met elkaar doorgebracht. Zowel 
op de zaak als op de golfbaan, racefiets of BOOT-OX. Je hebt alle pieken en dalen van 
het promoveren meegemaakt. Bedankt voor alle steun, vriendschap en gezelligheid. 
Beste Hugo, breur, ondanks dat je thuis al te veel medische verhalen vrijwillig ver-
plicht moest aanhoren, vind ik het extra bijzonder dat je mij vandaag wilt bijstaan als 
paranimf. Ik hoop dat we in de toekomst nog veel meer activiteiten en reizen mogen 
beleven. 
Beste Patrick, we hebben voor het eerst kennis gemaakt in het kader van het on-
derzoek naar families met de ziekte van Dupuytren. Je reisde samen met Olga het 
hele land door om deze families in kaart te brengen. We hebben sindsdien vele leuke 
activiteiten meegemaakt en we zijn goede vrienden geworden. Bedankt voor jullie 
hulp en interesse en natuurlijk de vele relativerende ‘sport’ sessies.
Lieve familie, bedankt voor jullie interesse. 
Pap en mam, bedankt voor jullie onvoorwaardelijke steun en vertrouwen. Van jongs 
af aan hebben jullie ons (Valérie, Hugo en ik) een warm en veilig nest geboden en 
gestimuleerd om te bereiken wat we voor ogen hadden. Pap, ik draag dit boek aan jou 
op, je had er zo graag bij willen zijn.
Lieve Denise, zonder jou was dit boekje er nooit gekomen. Je bent de belangrijkste 
persoon in mijn leven, samen met onze prachtige kinderen Julie en Jens. Bedankt voor 
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